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3Words are, in my not-so-humble opinion, our most inexhaustible source of magic.
Capable of both inflicting injury, and remedying it.
Albus Dumbledore in Harry Potter and the Deathly Hollows
by J.K. Rowling
4ABSTRACT
Carboxylesterases (CESs) catalyze the hydrolysis of a variety of ester- and
amide-containing compounds to their respective free acids. The main CES isozymes
involved in drug metabolism are carboxylesterases 1 and 2 (CES1 and CES2). CES1
contributes to an estimated 80 to 95% of the total hydrolytic activity in the human liver. A
CES1 c.428G>A (p.G143E, rs71647871) single nucleotide variation (SNV) markedly
decreases the catalytic efficiency of CES1 in vitro. Possible effects of this variant on drug
pharmacokinetics in vivo in humans, however, have not been systematically investigated.
Furthermore, only a few studies have investigated the effects of CES1 variants on its
expression and/or activity. Therefore, this thesis aimed to investigate genetic variability in
the CES1 gene in the Finnish population and their effects on drug pharmacokinetics and
pharmacodynamics in humans.
The frequency distribution of the CES1 c.428G>A SNV was investigated in 860 healthy
Finnish volunteers. The effects of the CES1 c.428G>A SNV on the pharmacokinetics of
oseltamivir, clopidogrel, quinapril, and enalapril were investigated in 40 healthy
volunteers. The CES1 gene and its flanking regions were sequenced in 192 healthy
volunteers to identify previously unknown variants affecting CES1 whole blood expression.
The findings were replicated in another set of 88 healthy volunteers. Furthermore, the
effects of the detected variants on CES1 liver expression were investigated in 177 liver
samples and on clopidogrel pharmacokinetics in 106 healthy volunteers from previous
pharmacokinetic studies on clopidogrel.
The CES1 c.428G>A variant allele was found with a minor allele frequency of 2.2%.
The c.428G>A SNV reduced the hydrolysis of oseltamivir to the active oseltamivir
carboxylate. The oseltamivir carboxylate to oseltamivir area under the plasma
concentration-time curve (AUC) ratio was 23% smaller in heterozygous carriers than
noncarriers. The c.428G>A SNV reduced the hydrolysis of clopidogrel to the inactive
carboxylic acid metabolite. Consequently, the AUC of the parent clopidogrel was about
120% higher and that of the active metabolite about 70% higher in carriers than in
noncarriers. Consistently, the c.428G>A SNV markedly enhanced the platelet inhibitory
effect of clopidogrel. The average percentage inhibition of platelet aggregation at 0-12
hours was 19% higher in carriers than in noncarriers. The c.428G>A SNV significantly
reduced the hydrolysis of enalapril to active enalaprilat. The AUC of enalaprilat was 20%
lower in carriers than in noncarriers. The c.428G>A SNV had no observable effect on the
pharmacokinetics of quinapril. Two intronic CES1 rs12443580 and rs8192935 SNVs were
discovered to have a major effect on CES1 expression in whole blood, but not the liver.
Moreover, these two SNVs had no effect on clopidogrel pharmacokinetics.
In conclusion, the CES1 c.428G>A SNV reduces the bioactivation of oseltamivir,
markedly increases the clopidogrel active metabolite plasma concentrations and antiplatelet
effects, and reduces the bioactivation of enalapril in vivo in humans. The two intronic CES1
rs12443580 and rs8192935 SNVs have tissue-specific effects on CES1 expression. This
could lead to substrate-dependent effects of these SNVs on drug biotransformation.
5YHTEENVETO
Karboksyyliesteraasit hydrolysoivat erilaisia esteri- ja amidirakenteisia yhdisteitä.
Lääkeaineiden hydrolyysiin osallistuvat lähinnä karboksyyliesteraasit 1 ja 2 (CES1 ja
CES2). CES1 katalysoi noin 80-95 % maksassa tapahtuvasta hydrolyysistä. CES1-geenissä
tunnetaan sen toimintaa in vitro heikentävä yhden nukleotidin muunnos (c.428G>A,
p.G143E, rs71647871), mutta sen vaikutuksia lääkkeiden farmakokinetiikkaan ei ole
aiemmin systemaattisesti tutkittu. Lisäksi muiden mahdollisten CES1-geenimuunnosten
vaikutuksista CES1:n ilmentymiseen ja/tai aktiivisuuteen on vain vähän tietoa.
Väitöskirjatyön tavoitteena oli tutkia CES1-geenimuunnosten esiintyvyyksiä suomalaisilla
sekä näiden geenimuunnosten vaikutuksia CES1:n ilmentymiseen sekä lääkeaineiden
farmakokinetiikkaan ja farmakodynamiikkaan ihmisillä.
CES1 c.428G>A geenimuunnoksen esiintyvyyttä tutkittiin 860 terveen vapaaehtoisen
koehenkilön otoksessa. CES1-geenimuunnoksen vaikutusta oseltamiviirin, klopidogreelin,
kinapriilin ja enalapriilin farmakokinetiikkaan tutkittiin yhteensä 40 terveellä
vapaaehtoisella koehenkilöllä. CES1-geeni sekvensoitiin 192 terveeltä vapaaehtoiselta
koehenkilöltä mahdollisten CES1:n ilmentymiseen kokoveressä vaikuttavien
geenimuunnosten löytämiseksi. Löydettyjen geenimuunnosten vaikutus toistettiin 88
terveen vapaaehtoisen aineistossa. Lisäksi geenimuunnosten vaikutusta tutkittiin CES1:n
ilmentymiseen maksassa 177 maksanäytteen aineistossa ja klopidogreelin
farmakokinetiikkaan 106 terveellä vapaaehtoisella koehenkilöllä aiemmin tehtyjä
farmakokineettisiä töitä hyödyntäen.
CES1 c.428G>A geenimuunnoksen esiintyvyys oli 2,2 %. CES1-geenimuunnos vähensi
oseltamiviirin metaboliaa aktiiviseksi oseltamiviirikarboksylaatiksi, minkä seurauksena
oseltamiviirikarboksylaatin ja oseltamiviirin pitoisuus-aikakäyrän alle jäävän pinta-alan
(AUC) suhde oli 23 % pienempi kantajilla kuin ei-kantajilla. CES1-geenimuunnos vähensi
klopidogreelin metaboliaa inaktiiviseksi karboksyylihappometaboliitiksi, minkä
seurauksena klopidogreelin AUC oli noin 120 % suurempi ja aktiivisen metaboliitin AUC
noin 70 % suurempi kantajilla kuin ei-kantajilla. Vastaavasti CES1-geenimuunnos lisäsi
merkittävästi klopidogreelin antitromboottista vaikutusta; 12 tunnin keskimääräinen
verihiutaleiden paakkuuntumisen esto oli 19 prosenttiyksikköä suurempi kantajilla kuin ei-
kantajilla. CES1-geenimuunnos vähensi enalapriilin metaboliaa aktiiviseksi
enalaprilaatiksi, minkä seurauksena enalaprilaatin AUC oli 20 % pienempi kantajilla kuin
ei-kantajilla. CES1-geenimuunnoksella ei ollut vaikutusta kinapriilin farmakokinetiikkaan.
Kaksi intronissa sijaitsevaa CES1-geenimuunnosta (rs12443580 ja rs8192935) vaikuttivat
merkittävästi CES1:n ilmentymiseen kokoveressä, mutta eivät maksassa. Näillä kahdella
geenimuunnoksella ei myöskään ollut vaikutusta klopidogreelin farmakokinetiikkaan.
Yhteenvetona voidaan todeta, että CES1 c.428G>A geenimuunnos heikentää
oseltamiviirin bioaktivaatiota, lisää klopidogreelin aktiivisen metaboliitin
plasmapitoisuuksia ja antitromboottista vaikutusta sekä heikentää enalapriilin
bioaktivaatiota. Kahden CES1-geenimuunnoksen (rs12443580 ja rs8192935) vaikutus
CES1:n ilmentymiseen vaikuttaa olevan kudosspesifistä ja siten niiden vaikutus
lääkeaineiden metaboliaan voi vaihdella eri aineiden välillä.
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1 INTRODUCTION
As Sir William Osler said, “If it were not for the great variability among individuals,
medicine might as well be a science and not an art”. In recent years, our understanding of
the influence of genes on interindividual variability has developed (Evans & McLeod 2003,
Eichelbaum et al. 2006, Daly 2010, EMA 2011). Genetic variability can affect all aspects
of a disease and its treatment, such as the rate of disease occurrence, the risk of disease
progression and recurrence, the most likely beneficial drug and its therapeutic dose, the
nature and extent of response to treatment, and the possibility of drug toxicity (FDA 2013).
Genetic variants can potentially lead to profound effects on the efficacy and/or safety of the
administered drug (EMA 2011, FDA 2013). Furthermore, genetic variants can influence
the effect size of an interacting drug (perpetrator drug) (EMA 2011). In pharmacogenetics,
genetic variants influencing or predicting the outcome of drug treatment are studied in
relation to efficacy of drug treatment and adverse reactions (EMA 2011, FDA 2013).
Cytochrome P 450 enzymes (CYPs) contribute to the metabolism of about 70% of
drugs, with most of the remaining drugs metabolized by uridine 5´-phosphate
glucuronosyltransferases (UGTs) and esterases, including carboxylesterases (Oda et al.
2015). The clinical significance of carboxylesterases (CESs) in the metabolism of drugs is,
however, not fully appreciated despite the large number of widely used drugs subject to
CES-mediated hydrolysis. Concomitant with the growing number of CES1 substrate drugs
increases awareness that genetic factors, as well as diseases and drug-drug interactions,
may alter the activity of CESs and significantly impact the therapeutic effects of their
substrate drugs (Imai 2006, Laizure et al. 2013).
CESs belong to an α,β-hydrolase-fold protein family and are expressed in many tissues,
especially the liver, small intestine, and lungs. CESs catalyze the hydrolysis of a variety of
ester- and amide-containing compounds to their respective free acids (Hosokawa 2008).
The main CES isozymes involved in drug metabolism are carboxylesterases 1 and 2 (CES1
and CES2). CES1 contributes to an estimated 80 to 95% of the total hydrolytic activity in
the human liver with the remaining hydrolytic activity being attributed to other esterases,
including CES2 (Imai 2006, Zhu & Markowitz 2013).
Several sequence variations have been found in the CES1 gene, some with functional
effects on CES1 activity (Zhu et al. 2008, Zhu & Markowitz 2009). The CES1 c.428G>A
missense (p.G143E, rs71647871) single nucleotide variation (SNV) is associated with a
reduced biotransformation of CES1 substrate drugs, such as methylphenidate (Zhu et al.
2008). A n.-816A>C (rs3785161) SNV residing upstream from the pseudogene CES1P1
has been associated with an increased antiplatelet response to clopidogrel, while an
association was recently found between intronic CES1 c.1168-33A>C (rs2244613) SNV
and decreased trough concentrations of active dabigatran and reduced bleeding risk. Only
a few studies, however, have investigated the effects of CES1 variants on its expression
and/or activity or on drug pharmacokinetics in vivo in humans.
Over 90% of the anti-influenza drug oseltamivir is rapidly hydrolyzed to active
oseltamivir carboxylate by CES1 in the liver (Shi et al. 2006). CES1 also hydrolyzes about
40-60% of the parent quinapril and enalapril to their active metabolites quinaprilat and
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enalaprilat (Laizure et al. 2013). The angiotensin converting enzyme (ACE) inhibitors,
quinapril and enalapril, are used in the treatment of hypertension and congestive heart
failure. Clopidogrel, on the other hand, is widely used in the prevention and treatment of
atherothrombotic diseases. Clopidogrel is a thienopyridine prodrug that is converted to an
active cis 5-thiol metabolite through an inactive intermediate 2-oxo-clopidogrel by CYPs
(Farid et al. 2010, Dansette et al. 2012). CES1, however, hydrolyzes about 90% of the
parent clopidogrel to an inactive clopidogrel carboxylic acid metabolite, which is further
metabolized by glucuronidation. In a previous in vitro study, the CES1 c.428G>A SNV
markedly affected clopidogrel metabolism (Tang et al. 2006). Moreover, clopidogrel active
metabolite plasma concentrations were about 60% higher in seven healthy Amish CES1
c.428G>A variant allele carriers than in non-carriers (Lewis et al. 2013).
Therefore, the purpose of this thesis was to investigate the frequency distribution of the
CES1 c.428G>A SNV in the Finnish population and the impact of this SNV on the
pharmacokinetics of oseltamivir and on the pharmacokinetics and pharmacodynamics of
clopidogrel, quinapril, and enalapril in prospective genotype panel studies. Furthermore,
we investigated the effects of CES1 genetic variants on its whole blood and liver expression
and on clopidogrel pharmacokinetics and pharmacodynamics.
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2 REVIEW OF THE LITERATURE
2.1 Pharmacogenetics
Although many nongenetic factors influence drug response, including age, organ function,
and drug interactions, there are numerous examples of cases in which interindividual
differences are due to variations in (1) genes relevant to the drug’s pharmacokinetics; (2)
genes encoding drug targets and other pathways related to the drug’s pharmacodynamics;
(3) genes that can predispose to toxicities such as immune reactions; and (4) genes that
influence disease susceptibility or progression (Evans & McLeod 2003, FDA 2013).
Pharmacogenetics studies the effects of DNA sequence variations on drug
pharmacokinetics, pharmacodynamics, efficacy, and adverse effects (Redon et al. 2006,
EMA 2007).
Human genetic variations range from single nucleotide changes to gains or losses of
whole chromosomes. Individuals differ from each other approximately every 300-1000
nucleotides, with an estimated total of 15 million single nucleotide variations (SNVs) and
thousands of deletions, insertions, duplications, and complex multi-site variants (termed
copy number variations (CNVs)) in the genome (Redon et al. 2006, Stranger et al. 2007,
1000 Genomes Project Consortium et al. 2010). Because 95% of the genome is intergenic,
most variations are unlikely to directly affect the encoded transcript or protein. Variations
in noncoding regions of genes may occur in the 3´ and 5´ untranslated regions (UTRs),
promoter or enhancer regions, or intronic regions essential for splice sites. Close to 45% of
the human genome can be recognized as transposons, mobile DNA sequences that can
migrate to different regions of the genome, although most transposons are no longer active
(Burns & Boeke 2012).
Coding region SNVs are classified as nonsynonymous (or missense), if the base pair
change results in an amino acid substitution, or synonymous (or sense), if the base pair
substitution within a codon does not alter the encoded amino acid. Base pair substitutions
that lead to a premature stop codon are termed nonsense mutations. Linkage equilibrium
occurs when the genotype present at one locus is independent of the genotype at the second
locus. Linkage disequilibrium (LD) occurs when the genotypes at the two loci are not
independent of one another. In complete LD, genotypes at two loci always occur together
(1000 Genomes Project Consortium et al. 2010).
Epigenetics refers to heritable patterns of gene expression that cannot be directly
attributed to changes in the primary DNA sequence (Ivanov et al. 2012, Ivanov et al. 2014).
The best known epigenetic mechanisms in humans are DNA methylation, posttranslational
modification of histone proteins, and modulation of gene expression by noncoding RNAs
(Ivanov et al. 2012). Approximately 60% of human genes contain CpG islands, i.e., regions
of the genome containing an unusually high number of CpG sites and tending to be located
in gene promoters (Ivanov et al. 2012). The hypermethylation of these CpG islands
correlates with repressed transcription (Ivanov et al. 2012). Histone modifications, such as
acetylation, methylation, and phosphorylation, affect the overall chromatin structure and in
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this way influence transcription and many other DNA processes such as repair, replication,
and recombination (Bannister & Kouzarides 2011, Ivanov et al. 2012). MicroRNAs
(miRNAs) are on average 22 nucleotides long, single-stranded, and regulate the expression
of selected sets of target genes by base pairing with their transcripts (Cheng et al. 2005,
Eulalio et al. 2008). Usually, the binding sites are in the 3´ UTR of target mRNA sequences,
and the bound miRNA inhibits translation to down-regulate expression of the target gene
(Cheng et al. 2005, Eulalio et al. 2008). Many thousands of long noncoding RNAs
(lncRNAs), with lengths of over 200 nucleotides, are also thought to be involved in gene
regulation (Yoon et al. 2013). Although the function of the great majority of the lncRNAs
are unknown, some are known to be associated with chromatin modification enzymes and
mediate gene activation and silencing (Yoon et al. 2013).
2.2 Human carboxylesterases
General aspects. Human carboxylesterases (CESs) (Enzyme Commission number 3.1.1.1)
are members of the serine esterase superfamily containing an α,β-hydrolase-fold and
comprise a multigene family (Hosokawa et al. 2007, Takahashi et al. 2008). CESs are
categorized as phase 1 drug-metabolizing enzymes and are responsible for the hydrolysis
of a wide variety of endogenous and exogenous compounds, including esters, thioesters,
carbamates, and amides to their respective free acids and alcohols (Satoh & Hosokawa
1998, Fukami et al. 2008, Hosokawa 2008, Laizure et al. 2013). CESs can be classified
into five major families (CES1-CES5) according to the homology of the amino acid
sequence (Hosokawa 2008). In general, carboxylesterases exhibit approximately 80%
sequence identity within a CES gene family (Satoh et al. 2002). The first carboxylesterases
were purified from human intestines and liver in 1979 and 1980 (Inoue et al. 1979, Inoue
et al. 1980). Later, the human liver carboxylesterase was shown to catalyze the hydrolysis
of the methyl ester group of cocaine to form benzoylecgonine (Brzezinski et al. 1994).
Genomic organization. The human CES gene family consists of five protein coding genes
(CES1, CES2, CES3, CES4A, and CES5A) and three pseudogenes (CES1P1, CES1P2, and
CES5AP1). CES1, CES5A, CES1P1, and CES1P2 are located in a cluster on chromosome
16 (16q12.2), while CES2, CES3, and CES4A are in a separate cluster on the same
chromosome (16q22.1). CES5AP1 is located on chromosome 22 (22q11.23). Different
isoforms are generated in vivo for each of the CES genes as a result of transcriptional events,
including truncation of the 5´ ends, differential presence or absence of exons, alternative
splicing or retention of introns, or overlapping exons with different boundaries (Holmes et
al. 2010).
Expression. The expression of carboxylesterases is ubiquitous with high levels in various
tissues (Satoh & Hosokawa 2006, Hosokawa 2008). Typically, expression of CESs is
maximal in the epithelia of most organs, suggesting that these enzymes play a protective
role against xenobiotics (Imai 2006). Among various tissues, the highest hydrolytic activity
16
is typically found in the liver, but it can also be found in several other tissues, such as lungs,
testes, kidneys, and brain (Satoh et al. 2002). Carboxylesterase activity in the liver is
predominantly found in the microsomal fraction, although significant carboxylesterase
activity is present in the lysosomal fraction, and the lysosomes contribute substantially to
the general esterolytic capacity of the liver (Satoh & Hosokawa 1998, Hosokawa 2008).
Smaller amounts of CESs are also present in the cytosolic fraction (Boberg et al. 2017).
CESs are localized in the luminal side of endoplasmic reticulum (ER) (Potter et al. 1998,
Imai 2006), through the binding of four amino acid residues at their C-terminal with the
KDEL (lycine – aspartic acid – glutamic acid – leucine) ER protein retention receptor (Imai
& Ohura 2010). Uridine 5´-diphosphate glucuronosyltransferases (UGTs) are colocalized
with CESs and have the potential to further metabolize carboxylic acids to acyl
glucuronides (Inoue et al. 2013). Carboxylesterase expression is highly regulated during
development by nutritional status, hormonal factors, and xenobiotics (Satoh & Hosokawa
2006).
Catalytic function. Carboxylesterases have a catalytic triad composed of serine, glutamate,
and histidine. These three amino acids are required for hydrolytic activity, with mutation
in one of these residues resulting in a catalytically inactive protein (Potter & Wadkins
2006). Carboxylesterases do not require cofactors such as inorganic ions (Liederer &
Borchardt 2006). The catalytic triad employs a two-step hydrolysis mechanism (Figure 1).
In the first step, a covalent acyl-enzyme intermediate is formed with the serine residue, and
the alcohol product is released (Liederer & Borchardt 2006, Potter & Wadkins 2006).
Histidine is required to activate the serine, and glutamate is in turn required to stabilize the
histidine residue (Liederer & Borchardt 2006, Potter & Wadkins 2006). In the second step,
a water molecule attacks the acyl-enzyme linkage, releasing the acyl product and
regenerating the enzyme (Liederer & Borchardt 2006, Potter & Wadkins 2006).
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Figure 1. Mechanism for the bioconversion of esters by carboxylesterases (adapted
from Liederer & Borchardt 2006 and Satoh & Hosokawa 2006). Glu,
glutamate; His, histidine; R1, radical 1; R2, radical 2; Ser, serine.
Role in drug disposition. Carboxylesterases have overlapping substrate specificities, and
drug substrates are often susceptible to hydrolysis by multiple carboxylesterases and other
esterases. One carboxylesterase, however, usually predominates with each substrate and
serves as the major pathway of hydrolysis (Laizure et al. 2013). The relatively high content
in different tissues may also compensate for the CESs relatively low catalytic efficiency for
substrates (Brzezinski et al. 1994). In humans, CES1 and CES2 are primarily responsible
for the hydrolysis of drugs (Oda et al. 2015). Recent studies have shown differences
between CES1 and CES2 families in terms of substrate specificity (Imai 2006). For a CES1
substrate drug that undergoes a high first-pass hydrolysis after oral administration, the
parent compound that escapes first-pass metabolism in the liver will be subject to
flow-dependent hepatic elimination due to the high CES1 content (Laizure et al. 2013). The
CES2 substrate drugs that escape first-pass hydrolysis and reach systemic circulation no
longer have direct access to CES2 in the small intestine (Laizure et al. 2013). Hydrolysis
can still occur in the liver as it posseses CES2 activity, but to a diminished degree compared
with the small intestine (Laizure et al. 2013). It is also possible that a CES2 substrate drug
could gain access to intestinal CES2 through enterohepatic recirculation (Laizure et al.
2013).
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2.3 Carboxylesterase 1
2.3.1 Genomic organization and expression
The CES1 gene subfamily is located on the chromosome 16 and is composed of three genes,
CES1 (a functional gene), CES1P1 (a pseudogene, previously termed CES1A3 and CES4),
and CES1P2 (a pseudogene) (Figure 2). The CES1 gene spans about 30 kb (Marsh et al.
2004) and consists of 14 exons encoding 567 amino acids (Yoshimura et al. 2008, Sai et
al. 2010). Exon 1 encodes a signal peptide (Hosokawa 2008). The nonfunctional CES1P1
pseudogene located in proximity with the CES1 gene, consists of six exons, and contains a
stop codon in exon 3 (Fukami & Yokoi 2012), while CES1P2 consists of 14 exons and
spans about 26 kb (Rasmussen et al. 2015). CES1P1 and CES1P2 are located in the opposite
direction compared to CES1 (Rasmussen et al. 2015).
Figure 2. CES1 and CES1P1 gene structures. CES1VAR is a variant of CES1 in which
the exon 1 is converted to that of CES1P1. CES1P1VAR is a variant of
CES1P1 which is identical to the CES1 gene except for the differences of five
nucleotides in exon 1. CES1, carboxylesterase 1; CES1P1, carboxylesterase
1 pseudogene.
CES1 is highly expressed in the liver and observed in other tissues, such as blood, the
small intestine, lungs, heart, and testes (Satoh & Hosokawa 1998, Satoh et al. 2002,
Redinbo et al. 2003, Hatfield et al. 2011, Kuhl et al. 2016), but not in plasma (Li et al.
2005). In accordance with the tissue expression profile of CES1, its promoter region is
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hypomethylated in the liver and hypermethylated in the kidney (Oda et al. 2015). CES1
contributes to 80-95% of total hydrolytic activity in the human liver, and the residual
hydrolytic activity is attributed to other esterases, such as CES2 (Imai 2006, Zhu &
Markowitz 2013). CES1 has a partially overlapping tissue expression profile with CES2
(Table 1). Additionally, interindividual CES1 expression levels seem to have greater
variation than CES2 expression levels (Liu et al. 2010, Boberg et al. 2017). CES1 and CES2
mRNA levels are significantly associated with the levels of respective proteins (Pope et al.
2005).
Table 1. Tissue-specific gene expression profiles of CES1 and CES2 isozymes in
humans.
Tissue CES1 CES2
Liver +++ +
Small intestine - +++
Kidney + +++
Lung +++ -
Adapted from (Hosokawa 2008).
-, not detected; +, weakly expressed; ++, moderately expressed; +++, strongly expressed.
CES1, carboxylesterase 1; CES2, carboxylesterase 2.
CES-mediated hydrolysis demonstrates a typical ontogeny of increasing activity as
development progresses from birth to adulthood (Laizure et al. 2013). Adults express
higher levels of CES1 and CES2 than children (<6 years) at both the mRNA and protein
levels (Zhu et al. 2009a, Shi et al. 2011, Hines et al. 2016, Boberg et al. 2017).
Additionally, the female sex is associated with increased CES1 mRNA expression in
adipose tissue (Friedrichsen et al. 2013). The CES1 mRNA expression in adipose tissue is
also positively correlated with measures of adiposity and metabolic function, such as body
mass index (BMI), increased waist circumference, triglyceride level, and plasma insulin
level (Jernas et al. 2009, Marrades et al. 2010, Nagashima et al. 2011, Friedrichsen et al.
2013).
Xenobiotics and pathological conditions can alter the expression of carboxylesterases.
In human primary hepatocytes, dexamethasone caused a slight induction of CES1 and
CES2 protein expression (Zhu et al. 2000). On the other hand, CES1 mRNA expression
was not induced by rifampicin or omeprazole, suggesting that pregnane X receptor (PXR)
and aryl hydrocarbon receptor (AhR) are not involved in the transactivation of CES1
(Nishimura et al. 2002, Oda et al. 2015). In human hepatocellular carcinoma (HepG2) cells,
nuclear factor-erythroid 2-related factor 2 (NRF2) agonists, sulphorophane and
tert-butylhydroquinone, induced CES1 mRNA levels and increased CES1 protein
expression and enzyme activity via an antioxidant response element at the distal promoter
sequence -2025 bp from the translation start site (TSS) (Maruichi et al. 2010). The
proinflammatory cytokine interleukin-6 (IL-6) has been implicated in decreasing the
expression of CES1 and CES2 both at mRNA and protein levels by 20-60% and the
decrease was comparable with the decrease in the hydrolytic activity (Yang et al. 2007).
Furthermore, the IL-6 mediated suppression also altered cellular responsiveness to
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therapeutic agents, such as clopidogrel, irinotecan, and oseltamivir in vitro (Yang et al.
2007). CES1 expression is additionally regulated by hepatocyte nuclear factor 4Į (HNF4Į)
via binding to the direct repeat element between -287 and -300 bp from the transcription
start site (Xu et al. 2016). In patients with alcoholic liver steatohepatitis, CES1 expression
is reduced both at the mRNA and protein levels by 75-85%, likely through ethanol-
mediated inhibition of HNF4Į (Xu et al. 2016). In patients with steatosis or nonalcoholic
steatohepatitis, hepatic CES2 protein level is also reduced by about 50%-60%, likely
through inhibition of HNF4Į (Li et al. 2016). In addition, CES1 expression is regulated by
specificity protein 1 (Sp1) and CCAAT/enhancer binding protein (C/EBP). Sp1 binding
sites are located at -195 bp and -84 bp from the TSS and a C/EBP element at -290 bp
(Hosokawa et al. 2008).
2.3.2 Structure and catalytic mechanism
CES1 consists of 567 amino acid residues (Zhu et al. 2008). Crystal structures of human
CES1 have been reported in complexes with several substrates, and the crystal structure of
CES1 with tacrine is shown in Figure 3 (Bencharit et al. 2003). The monomeric molecular
weight of CES1 is approximately 60 kDa (Brzezinski et al. 1994, Takai et al. 1997, Fukami
& Yokoi 2012). It exists in a trimer-hexamer equilibrium that can be shifted toward trimer
through binding of compounds to a site on the surface of the enzyme (Bencharit et al. 2003).
The monomeric CES1 enzyme comprises of three structural domains: a central catalytic
domain, an α,β-domain, and a regulatory domain (Staudinger et al. 2010). The central
catalytic domain contains the serine hydrolase catalytic triad, whereas the regulatory
domain contains the low-affinity surface ligand-binding Z-site, which controls the trimer-
hexamer equilibrium (Potter & Wadkins 2006, Bencharit et al. 2006, Staudinger et al.
2010).
The active site of CES1 is buried at the bottom of a long gorge (Potter & Wadkins
2006). The gorge is lined with aromatic amino acids, creating a highly hydrophobic pocket
and an electrostatic gradient that essentially “sucks” substrate molecules towards the
catalytic amino acid residues (Bencharit et al. 2003, Potter & Wadkins 2006). At the base
of the active site gorge, the catalytic serine (221), histidine (468), and glutamic acid (354)
residues are juxtaposed so that nucleophilic attack of esterified substrates can readily take
place (Bencharit et al. 2003, Potter & Wadkins 2006, Bencharit et al. 2006). Adjacent to
these amino acids is an oxyanion hole (glycines 141-143) that stabilizes tetrahedral
substrate-enzyme intermediates and is evolutionarily conserved across species and within
related serine hydrolases (Potter & Wadkins 2006). A side door also exists within CES1
that allows rapid removal of the hydrolysis products from the active site, increasing the
efficacy of substrate turnover, especially for large bulky substrates (Fleming et al. 2005,
Potter & Wadkins 2006).
In addition to hydrolytic reactions, CES1 has been shown to catalyze transesterification
(Brzezinski et al. 1994, Morgan et al. 1994). Compounds other than water can attack the
covalent acyl-enzyme intermediate, leading to transesterification rather than hydrolysis,
especially with hydrophobic alcohols (Dean et al. 1991, Bencharit et al. 2003, Imai 2006).
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Figure 3. Crystal structure of CES1 with tacrine (Bencharit et al. 2003). A) A trimer of
CES1 in complex with tacrine viewed down the 3-fold axis of symmetry and
into the catalytic gorge of each monomer. The catalytic domains of each
monomer are in blue, green, and red. B) A molecular surface of the CES1
hexamer with a ribbon representation of one pair of dimers within the
hexamer superimposed. Each CES1 monomer is labeled from Mol1 to Mol6.
CES1, carboxylesterase 1. Reprinted with the permission of the copyright
holder.
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2.3.3 Substrates
CES1 preferentially hydrolyzes compounds with a small alcohol moiety and large acyl
moiety (Satoh et al. 2002, Imai 2006, Hatfield et al. 2010). In addition to the relative sizes
of the alcohol and acyl moieties, the shapes of respective moieties likely contribute to the
hydrolytic preference as well, particularly when the alcohol and acyl moieties have similar
molecular weights (Tang et al. 2006). Although most CES1 substrates are esters, thioesters,
amides, and carbamates are also potential substrates (Figure 4).
Figure 4. Chemical structures of different types of CES1 substrates. CES1,
carboxylesterase 1; R1, radical 1; R2, radical 2; R3, radical 3.
CES1 metabolizes many cardiovascular drugs, such as angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II receptor blockers (ARBs), antithrombotics, and statins
(Table 2) (Laizure et al. 2013). ACE inhibitors, except captopril and lisinopril, are ester
prodrugs hydrolyzed by CES1 to their corresponding active carboxylic acid metabolites.
Three ARBs, candesartan, olmesartan, and azilsartan, are also ester prodrugs hydrolyzed
by CES1, although the main esterase involved in their metabolism is CES2 during
absorption in the small intestine (Laizure et al. 2013, Ishizuka et al. 2013). Three
antiplatelet drugs aspirin, clopidogrel, and prasugrel are subject to CES-mediated
hydrolysis. Clopidogrel, its inactive intermediate 2-oxo-clopidogrel, and the active cis 5-
thiol metabolite are hydrolyzed by CES1, but aspirin and prasugrel are mainly metabolized
by CES2 (Tang et al. 2006, Laizure et al. 2013). Anticoagulant dabigatran etexilate is a
prodrug that is rapidly hydrolyzed by esterases, notably CES1, to active dabigatran, a
reversible direct thrombin inhibitor (Pare et al. 2013, Shi et al. 2016c). The CES1 substrate
drugs affecting the central nervous system (CNS) can be divided into three therapeutic
categories: stimulants, opioid agonists, and anticonvulsants (Laizure et al. 2013). Some
psychoactive synthetic cannabimimetic drugs are also metabolized by CES1 (Thomsen et
al. 2015). The immunosuppressant drug mycophenolate mofetil and antiviral drug
oseltamivir phosphate are bioactivated by CES1-catalyzed hydrolysis (Shi et al. 2006,
Laizure et al. 2013). The two known CES1 carbamate substrates are oncologic drugs
irinotecan and capecitabine (Laizure et al. 2013).
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Table 2. Drugs that are metabolized by CES1.
Substrate Therapeutic use
and/or drug class
Hydrolysis
product
(activity)
Other
metabolizing
enzymes
References
Azilsartan
medoxomil
Antihypertensive,
ARB
Azilsartan
(active)
CES2
CMBL
Ishizuka et al. 2013
Benazepril Antihypertensive,
ACE inhibitor
Benazeprilat
(active)
Takai et al. 1997
Candesartan
cilexetil
Antihypertensive,
ARB
Candesartan
(active)
CES2
CMBL
Ishizuka et al. 2013
Capecitabine Oncologic 5’-deoxy-5-
fluorocytidine
(inactive)
CES2
CDA
TP
UPP1
UPP2
Quinney et al. 2005,
Hamzic et al. 2017
Ciclesonide Anti-inflammatoric Des-isobutyryl-
ciclesonide
(active)
CYP3A4 Mutch et al. 2007
Clopidogrel Antithrombotic Clopidogrel
carboxylic acid
(inactive)
CYP2C19
CYP1A2
CYP2B6
CYP3As
CYP2C9
UGTs
Tang et al. 2006,
Zhu et al. 2013
Cocaine Stimulant Benzoylec-
gonine
(inactive)
CES2
BChE
Brzezinski et al. 1994
Dabigatran
etexilate
Anticoagulant Dabigatran
(active)
CES2 Laizure et al. 2014
Enalapril Antihypertensive,
ACE inhibitor
Enalaprilat
(active)
Pang et al. 1991,
Thomsen et al. 2014,
Holenarsipur et al.
2015
Flumazenil Antidote Flumazenil acid
(inactive)
CYPs Kleingeist et al. 1998
Heroine Analgesic 6-acetyl-
morphine
(inactive)
CES
BChE
Dean et al. 1991,
Brzezinski et al. 1997,
Hatfield et al. 2010
Imidapril Antihypertensive,
ACE inhibitor
Imidaprilat
(active)
Takai et al. 1997,
Geshi et al. 2005
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Irinotecan
(CPT-11)
Oncologic 7-ethyl-10-
hydroxy-
camptotecin
(SN-38)
(active)
CES2
UGT1A1
UGT1A7
UGT1A9
CYP3A4
CYP3A5
Takai et al. 1997,
Humerickhouse et al.
2000,
Fujiwara & Minami
2010
Lovastatin Antihyperlipidemic Dihydroxy acid
metabolite
(active)
CES2
CYPs
Halpin et al. 1993,
Parker & Laizure 2010
Methylphenidate ADHD Ritalinic acid
(inactive)
Sun et al. 2004
Mycophenolate
mofetil
Immunosuppressant Mycophenolate
(active)
CES2
UGT1A9
UGT2B7
Fujiyama et al. 2010
Olmesartan
medoxomil
Antihypertensive,
ARB
Olmesartan
(active)
CMBL
CES2
Ishizuka et al. 2013
Oseltamivir Antiviral Oseltamivir
carboxylate
(active)
Shi et al. 2006
Oxybutynin Antispasmodic,
incontinence
2-cyclohexyl-2-
phenylglycolic
acid
(inactive)
CYP3A4
CES2
Sato et al. 2012
Pethidine
(meperidine)
Analgesic Meperidinic acid
(inactive)
Zhang et al. 1999
Quinapril Antihypertensive,
ACE inhibitor
Quinaprilat
(active)
CES2 Takai et al. 1997
Ramipril Antihypertensive,
ACE inhibitor
Ramiprilat
(active)
Meyer et al. 2015
Rufinamide Epilepsy Rufinamide
carboxylate
(inactive)
Williams et al. 2011b
Sacubitril Heart failure,
neprilysin inhibitor
LBQ657
(active)
Shi et al. 2016b
Simvastatin Antihyperlipidemic Dihydroxy acid
metabolite
(active)
CES2
CYP3A4
Vickers et al. 1990,
Parker & Laizure 2010
Tefinostat Oncologic CHR-2847
(active)
Ossenkoppele et al.
2013
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Ticlopidine Antithrombotic UR-4501
(active)
CYP1A2
CYP2B6
CYP2C19
CYP2D6
CYP3A4
PON1
Kim et al. 2014
Trandolapril Antihypertensive,
ACE inhibitor
Trandolaprilat
(active)
Zhu et al.
2009b
ACE, angiotensin-converting enzyme; ADHD, attention deficit hyperactivity disorder; ARB,
angiotensin II receptor blocker; BChE, butyrylcholinesterase; CDA, cytidine deaminase; CES1,
carboxylesterase 1; CES2, carboxylesterase 2; CMBL, carboxymethylenebutenoledase; CYP,
cytochrome P 450; PON1, paraoxonase 1; TP, thymidine phosphorylase; UPP1, uridine
phosphorylase 1; UPP2, uridine phosphorylase 2; UGT, uridine 5´-phosphate
glucuronosyltransferase
2.3.4 Pharmacogenetics of carboxylesterase 1
CES1 variants and functional studies. Over 1000 SNVs have been found in the CES1
gene (Wang et al. 2016), with the majority of the variants located in introns. All
nonsynonymous and essential splice site variants of CES1 described in the 1000 Genomes
project database are listed in the Table 3 with their continental frequencies and in silico
predicted effects on protein function.
Most of the nonsynonymous variants are rare and occur at a minor allele frequency
(MAF) of less than 1%. Only one of the nonsynonymous SNVs, c.34T>G (p.S12A,
rs12149366), occurs at a MAF of more than 5% in all investigated populations (5% in
African, 7% in European, 7% in South Asian, and 8% in East Asian populations,
respectively). Two other SNVs, c.500C>G (p.T167S, rs147694791) and c.805G>T
(p.A269S, rs115629050), are also found with frequencies of 6% and 9% in African
population and one SNV, c.19A>G (p.I7V, rs114788146), with a frequency of 6% in South
and East Asian populations. Three CES1 SNVs lead to a premature stop codon, c.119T>G
(rs151291296), c.310C>T (rs5023780), and c.1108G>T (rs185780477), and probably to a
nonfunctional enzyme, but they appear to be extremely rare with a MAF below 1%. Seven
predicted loss-of-function splice site variants have been reported as well. A common splice
donor variant in intron 7, c.903+1G>T (rs4513095), occurs with a MAF of 5% in East
Asian and South Asian populations.
The functional effects of nonsynonymous CES1 variants have been investigated using
recombinantly expressed variant proteins and human liver microsomes. The most studied
nonsynonymous SNV, c.428G>A (p.G143E, rs71647871, previously rs121912777), in the
CES1 gene is located in exon 4. The glycine at position 143 constitutes a part of an oxyanion
hole and genetic variations leading to an amino acid change in this position impair the
catalytic function of CES1 (Fleming et al. 2005, Zhu et al. 2008). The MAF of the CES1
c.428G>A SNV is about 2-4% in Caucasian, 4% in African-American, and 0% in Asian
populations (Zhu et al. 2008, Walter Soria et al. 2010). The CES1 c.428G>A SNV has no
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effect on CES1 protein expression level in the liver (Shi et al. 2016c). The CES1 c.428G>A
SNV, however, markedly decreases the catalytic efficiency of CES1 in vitro (Zhu et al.
2008), resulting in a complete loss of hydrolytic activity towards methylphenidate and
trandolapril (Zhu et al. 2008, Zhu et al. 2009b). The CES1 c.428G>A SNV reduces the
hydrolysis of clopidogrel, 2-oxo-clopidogrel, and the active cis 5-thiol metabolite to their
corresponding inactive carboxylic acid derivatives in vitro (Hagihara et al. 2009, Zhu et al.
2013). Similarly, the CES1 c.428G>A SNV reduced the hydrolysis of dabigatran etexilate
to the active dabigatran in vitro (Shi et al. 2016c). The intrinsic clearances of the model
substrate para-nitrophenyl acetate (PNPA) and oseltamivir have been reduced by about
80% in cell lines recombinantly expressing the p.G143E variant protein compared to the
wild-type CES1 (Zhu et al. 2008, Zhu & Markowitz 2013).
The CES1 c.53G>T (p.G18V, rs3826190), c.245C>T (p.S82L, rs62028647), and
c.805G>T (p.A269S, rs115629050) variants have had no significant effect on the CES1
protein expression levels or bioactivation of methylphenidate, oseltamivir, clopidogrel, or
enalapril (Zhu et al. 2013, Zhu & Markowitz 2013, Wang et al. 2016). In a population
pharmacokinetic study, however, the c.805G>T SNV was associated with a reduced
clearance of methylphenidate (Lyauk et al. 2016).
Two intronic CES1 SNVs, c.1168-33A>C (rs2244613) and c.257+885T>C
(rs8192935), have had no significant effect on the CES1 protein expression levels in the
liver (Shi et al. 2016c). These SNVs also had no effect on the hydrolysis of oseltamivir or
dabigatran etexilate in vitro (Shi et al. 2016a, Shi et al. 2016c).
A deletion in CES1P1 exon 6, c.780delT (p.D260fs, rs71647872), results in a frameshift
mutation that changes aspartic acid at position 260 to glutamic acid and alters the next 39
residues, before truncating early at a premature stop codon (Zhu et al. 2008). The intrinsic
clearances of PNPA and trandolapril have been reduced by about 100% in cell lines
recombinantly expressing the p.D260fs variant protein compared to the wild-type CES1
(Zhu et al. 2008).
An n.-816A>C SNV (rs3785161) in the promoter region of CES1P1 have had no
significant effect on oseltamivir hydrolysis in vitro (Shi et al. 2016a). The MAF of the
n.-816A>C SNV is about 25% in Asian population (Geshi et al. 2005).
Table 3. Nonsynonymous and essential splice site variants of CES1 described in the
1000 Genomes project database.
Variant allele frequency In silico prediction
dbSNP ID Nucleotide
change
Amino acid
change/
Splicing
variant
African European East
Asian
South
Asian
SIFT PolyPhen
Exon1
rs368050410 c.6G>T p.W2C - - - - tolerated benign
rs111604615 c.11G>C p.R4P 0.0121 0.004 0.0109 0.0174 tolerated benign
rs201577108 c.16T>C p.F6L - - - - tolerated benign
rs114788146 c.19A>G p.I7V 0.0234 0.0348 0.0556 0.0552 tolerated benign
rs116258771 c.31C>A p.L11I - - - - tolerated benign
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rs12149366 c.34T>G p.S12A 0.0507 0.0666 0.0804 0.0726 tolerated benign
Intron 1
rs139063675 c.52+1G>A Splice donor
variant
0.003 0 0 0 - -
Exon 2
rs3826190 c.53G>T p.G18V - - - - deleterious probably
damaging
rs142474691 c.65C>T p.S22L - - - - tolerated benign
rs3826192 c.112G>A p.V38I - - - - tolerated benign
rs140555786 c.116G>T p.S39I - - - - tolerated benign
rs151291296 c.119T>G p.L40Ter 0.0061 0 0 0 - -
rs142469038 c.131C>T p.A44V - - - - tolerated benign
rs114632091 c.145A>G p.I49V - - - - tolerated benign
rs3826193 c.145A>G p.I49V - - - - tolerated benign
rs372817758 c.154G>A p.G52R - - - - deleterious probably
damaging
rs3177828 c.167C>G p.A56G - - - - deleterious probably
damaging
rs75463934 c.176C>T p.P59L - - - - deleterious probably
damaging
rs2307240 c.224G>A p.S75N - - - - tolerated benign
rs373547343 c.233A>G p.K78R - - - - tolerated possibly
damaging
rs139250836 c.242C>T p.T81I - - - - deleterious possibly
damaging
rs62028647 c.245C>T p.S82L - - - - deleterious possibly
damaging
rs144498758 c.254C>T p.P85L - - - - deleterious possibly
damaging
Exon 3
rs149261413 c.259T>C p.C87R - - - - deleterious probably
damaging
rs202111709 c.278C>T p.A93V - - - - tolerated benign
rs375565319 c.288A>T p.L96F - - - - tolerated benign
rs5023780 c.310C>T p.R104Ter - - - - - -
rs201285602 c.311G>A/C p.R104Q/P - - - - tolerated/
deleterious
benign
rs28760313 c.338C>T p.S113F - - - - deleterious probably
damaging
rs368654524 c.355C>G p.L119V - - - - deleterious probably
damaging
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Exon 4
rs538274902 c.422G>C p.G141A 0.0008 0 0 0 deleterious probably
damaging
rs121912777 c.425G>A/C p.G142E/A - - - - deleterious probably/
possibly
damaging
rs71647871 c.428G>A p.G143E - - - - deleterious probably
damaging
rs146456965 c.439G>T p.G147C - - - - deleterious probably
damaging
rs369026668 c.443C>T p.A148V - - - - deleterious benign
rs187158640 c.466G>A p.A156T 0 0 0.001 0 deleterious benign
rs202121317 c.473C>T p.A158V - - - - deleterious possibly
damaging
rs372957576 c.487G>A p.V163M 0 0 0.001 0 deleterious probably
damaging
rs147694791 c.500C>G p.T167S 0.0613 0 0 0 tolerated possibly
damaging
rs143718310 c.506A>C p.Q169P - - - - deleterious probably
damaging
rs148947808 c.508T>G p.Y170D - - - - deleterious probably
damaging
rs201065375 c.511C>T p.R171C - - - - deleterious probably
damaging
rs369300055 c.512G>T p.R171L 0.0008 0 0 0.001 deleterious probably
damaging
rs4784575 c.518G>A p.G173D - - - - deleterious probably
damaging
Exon 5
rs200227274 c.556C>T p.R186W - - - - deleterious probably
damaging
rs60054861 c.557G>A/C p.R186Q/P - - 0.0 0.0 tolerated benign
rs373720580 c.566G>C p.W189S - - - - deleterious probably
damaging
rs150241462 c.568G>T p.G190C 0.0045 0 0 0 deleterious probably
damaging
rs552379877 c.569G>T p.G190V 0 0 0 0.001 deleterious probably
damaging
rs184487882 c.575T>C p.L192P - - - - deleterious probably
damaging
rs141471293 c.587C>A p.A196D - - - - deleterious probably
damaging
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rs563293177 c.595C>T p.R199C - - - - deleterious possibly
damaging
rs2307243 c.596G>A p.R199H - - - - tolerated benign
rs2307227 c.609C>A p.D203E - - - - tolerated benign
rs541646274 c.647C>T p.T216I - - - - deleterious probably
damaging
rs200707504 c.659A>G p.E220G 0 0 0.005 0 tolerated benign
rs543499053 c.674A>G p.E225G 0.0008 0 0 0 tolerated possibly
damaging
Exon 6
rs201251252 c.781G>A p.V261I - - - - tolerated benign
Exon 7
rs376597833 c.799C>A p.Q267K - - - - tolerated benign
rs115629050 c.805G>T p.A269S 0.0877 0.0388 0.0149 0.046 deleterious possibly
damaging
rs373607981 c.821G>A p.C274Y - - - - deleterious probably
damaging
rs200489319 c.829A>G p.T277A 0 0 0.001 0 deleterious benign
rs114119971 c.852C>G p.H284Q 0 0.0089 0 0 tolerated benign
rs144078935 c.859C>T p.R287Ter - - - - - -
rs560426140 c.860G>T p.R287L 0 0 0 0.002 deleterious possibly
damaging
rs202001817 c.869C>T p.T290M - - - - deleterious possibly
damaging
Intron 7
rs4513095 c.903+1G>T Splice donor
variant
0.0038 0.0109 0.0585 0.0562 - -
rs140353865 c.904-1G>A/T Splice acceptor
variant
- - - - - -
Exon 8
rs537106281 c.904A>G p.K302E 0 0 0.001 0 tolerated benign
rs142855408 c.929G>T p.G310V - - - - deleterious benign
rs201879239 c.935C>A p.P312H - - - - deleterious probably
damaging
Exon 9
rs138161688 c.958G>A p.G320S - - - - tolerated benign
rs368170439 c.968T>C p.I323T - - - - deleterious benign
rs564847260 c.994C>A p.P332T - - - - deleterious possibly
damaging
rs543385969 c.1000G>A p.E334K 0 0 0 0.001 deleterious benign
rs576295379 c.1020T>G p.N340K 0 0 0 0.0102 tolerated benign
rs374924526 c.1026C>G p.H342Q - - - - tolerated benign
rs145135221 c.1039A>G p.M347V 0 0 0 0.001 deleterious benign
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rs571865256 c.1081A>G p.M361V 0.0008 0 0 0 tolerated benign
Intron 9
rs112251452 c.1083+2T>A Splice donor
variant
- - - - - -
rs368234376 c.1084-1G>T Splice acceptor
variant
- - - - - -
rs201120164 c.1084-2A>T Splice acceptor
variant
- - - - - -
Exon 10
rs146595460 c.1097A>G p.Y366C 0 0 0 0.001 tolerated probably
damaging
rs185780477 c.1108G>A/T p.E370K/Ter 0 0 0.002 0 tolerated benign
rs140704082 c.1135A>G p.M379V 0 0.001 0 0 tolerated benign
rs201004290 c.1145T>G p.L382R 0 0 0.001 0 deleterious probably
damaging
Exon 11
rs149663601 c.1198A>G p.T400A - - - - tolerated benign
rs201990303 c.1201G>T p.E401Ter - - - - - -
rs199540213 c.1205A>T p.K402I - - - - deleterious benign
rs370123191 c.1227C>G p.D409E - - - - deleterious benign
rs200736792 c.1238A>T p.K413M - - - - tolerated benign
rs372638605 c.1288T>G p.S430A - - - - tolerated benign
rs114277361 c.1295T>C p.I432T - - - - tolerated benign
rs376976316 c.1303C>T p.R435W - - - - deleterious possibly
damaging
rs145088728 c.1304G>A p.R435Q 0.0008 0 0 0 tolerated possibly
damaging
Intron 11
rs74322122 c.1315+1G>A
/C
Splice donor
variant
- - - - - -
Exon 12
rs201158237 c.1405G>A p.G469R - - - - deleterious probably
damaging
Exon 13
rs200368245 c.1486G>A p.V496M - - - - tolerated benign
Nucleotide positions are given in relation to the full length CES1 mRNA sequence
(NM_001025194.1) and amino acid positions in relation to the respective protein sequence
(NP_001020365.1). Variant allele frequency data are from the 1000 Genomes project for
populations with African, European, South Asian, and East Asian ancestry
(www.1000genomes.org; 1000 Genomes Project Consortium et al. 2012). SIFT and PolyPhen
predictions of the possible impact of amino acid substitutions on protein function were obtained
using the Variant Effect Predictor (Kumar et al. 2009, Adzhubei et al. 2010, McLaren et al. 2010).
SIFT, sorting intolerant from tolerant; Ter, premature stop codon.
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Effects on drug response in humans. The CES1 c.428G>A SNV reduces the inactivation
of methylphenidate to ritalinic acid (Zhu et al. 2008, Stage et al. 2017) and, therefore,
reduces the required dose of methylphenidate for symptom reduction and increases the risk
of adverse effects (e.g., worsening of appetite reduction) (Nemoda et al. 2009, Bruxel et al.
2013). In one study, the clopidogrel active cis 5-thiol metabolite plasma concentration,
measured 1 hour after clopidogrel intake, was about 60% higher in seven healthy Amish
individuals with the c.428G/A genotype than in individuals with the c.428G/G genotype
(Lewis et al. 2013). In addition, individuals with the c.428G/A genotype had a better
clopidogrel response as measured by adenosine diphosphate (ADP) stimulated platelet
aggregation (Lewis et al. 2013).
A SNV located in the 5´-UTR of CES1, c.-75G>T (rs3815583), has been associated
with hepatotoxicity of isoniazid in patients with latent tuberculosis infection (Yamada et
al. 2010). Moreover, it has been associated with an increased risk of adverse effects, such
as appetite reduction and sadness, in attention deficit hyperactivity disorder (ADHD)
patients treated with methylphenidate (Yamada et al. 2010, Bruxel et al. 2013, Wang et al.
2016). The exact impact of the SNV on the CES1 enzyme is yet unknown, but, as it is
located at the 5´-UTR, it could effect gene regulation (Bruxel et al. 2013). The allele
frequency of this SNV is about 20% (Bruxel et al. 2013).
The CES1 c.1168-33A>C (rs2244613) SNV has been associated with reduced
dabigatran trough concentrations (by 15% per minor allele) and the c.257+885T>C
(rs8192935) SNV with reduced dabigatran peak plasma concentrations (by 12% per minor
allele) at genome-wide significance with a gene-dose effect (Pare et al. 2013). The CES1
c.1168-33A>C SNV was also associated with a lower risk of bleeding with an odds ratio
of 0.67 per minor allele (Pare et al. 2013). The CES1 c. 1168-33A>C SNV is also associated
with sadness as a side effect of methylphenidate treatment (Johnson et al. 2013). These two
CES1 SNVs are in linkage disequilibrium (r2=0.45 and D´=1.00) (Pare et al. 2013).
A CES1 c.1315+2025A>C (rs8192950) SNV in intron 1 has been associated with
decreased risk of ischemic events in Chinese patients on dual antiplatelet therapy with
aspirin and clopidogrel (Zhao et al. 2016).
An n.-816A>C SNV (rs3785161) in the promoter region of CES1P1 has been associated
with the blood pressure lowering effect of imidapril (Geshi et al. 2005). In one study, this
SNV also associated with attenuated platelet reactivity to clopidogrel in coronary heart
disease patients (Xie et al. 2014). This finding was not, however, replicated in another study
(Zou et al. 2014).
A haplotype consisting of three SNVs in the CES1 gene, c.690+129delC (rs3217164),
c.1168-41C>T (rs2244614), and c.1168-33C>A (rs2244613), and two SNVs in the
CES1P1 gene, n.95+346T>C (rs7187684) and n.-1232A>G (rs11861118), was recently
found to be associated with overall toxicity of capecitabine (Hamzic et al. 2017).
CES1 structural variation. A functional CES1P1 variant gene (CES1P1VAR, previously
termed CES1A2) is identical to the CES1 gene except for differences of five nucleotides
(four amino acids) in the signal peptide region in exon 1 and differences in promoter,
5´-UTR, and part of intron 1 (see Figure 2, section 2.3.1 Genomic organization and
expression) (Tanimoto et al. 2007, Fukami & Yokoi 2012, Zhu & Markowitz 2013,
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Rasmussen et al. 2015, Bjerre et al. 2017). The mature protein encoded by CES1P1VAR is
identical to that of CES1 (Zhu & Markowitz 2013). Within 1 kb of the upstream region,
CES1 has a C/EBP binding site and two Sp1 binding sites, whereas CES1P1/CES1P1VAR
only has one Sp1 binding site and no C/EBP binding site (Oda et al. 2015). The exon 1 of
the CES1 gene can also be converted to that of CES1P1 resulting in a CES1 variant
(CES1VAR) (Wang et al. 2016). The expression and activity of CES1VAR are similar to
those of CES1 (Wang et al. 2016). A rare variant of CES1 (CES1SVAR) contains only the
5´-UTR of CES1P1 (Bjerre et al. 2017).
In the liver, a majority of CES1 is the product of the CES1 gene because the
transcription efficiency of the CES1P1VAR is only about 2% of that of CES1 (Zhu  &
Markowitz 2013). Therefore, only CES1 genetic variants, and not those of CES1P1 or
CES1P2, are likely to significantly affect CES1 expression and activity. In line with this,
the CES1P1/CES1P1VAR genotype had no significant effect on the pharmacokinetics of
oseltamivir (Suzaki et al. 2013, Shi et al. 2016a) or the CES1/CES1VAR genotype on the
pharmacokinetics of methylphenidate (Stage et al. 2017). Since pseudogenes can affect the
mRNA levels of their protein-coding counterparts, however, CES1P1 and CES1P2 could
potentially modulate the level of CES1 mRNA (Friedrichsen et al. 2013).
2.3.5 Drug-drug interactions
Since ester derivatives are widely used as prodrugs, carboxylesterases are major
determinants of the pharmacokinetic behavior of most prodrugs, and the activity can be
influenced by interactions with a variety of compounds, either directly or by enzyme
regulation (Satoh & Hosokawa 2006). The evidence from in vitro and in vivo studies
suggests that drug-drug, drug-disease, and drug-food interactions could be important
factors affecting the therapeutic activity of drugs than the substrates of CES1 and/or CES2
(Li et al. 2007, Yang et al. 2007, Laizure et al. 2013).
Several potent CES1 inhibitors have been found by using recombinantly expressed
variant proteins, human liver s9 fractions, human liver microsomes, and human liver
homogenates (Table 4). The hydrolysis of imidapril to active imidaprilat by recombinant
CES1 is inhibited by several cardiovascular drugs, such as simvastatin lactone, lovastatin
lactone, glibenclamide, pioglitazone, rosiglitazone, troglitazone, telmisartan, nitrendipine,
diltiazem, and felodipine by as much as 80-100% in vitro (Fukami et al. 2010, Yanjiao et
al. 2013). The HIV-protease inhibitor nelfinavir inhibits the hydrolysis of methylphenidate
to inactive ritalinic acid in a concentration-dependent matter by about 50% in vitro
(Rhoades et al. 2012). In addition, aripiprazole, perphenazine, thioridazine, and fluoxetine
inhibit methylphenidate metabolism (Zhu et al. 2010, Rhoades et al. 2012). At equal
concentrations, clopidogrel inhibits the hydrolysis of oseltamivir to active oseltamivir
carboxylate by as much as 90% and at 10% concentration by as much as 55% (Shi et al.
2006). ACE inhibitors trandolapril and enalapril inhibit clopidogrel hydrolysis and increase
the formation of 2-oxo-clopidogrel and the active cis 5-thiol metabolite (Kristensen et al.
2014). Simvastatin inhibits clopidogrel hydrolysis in a concentration dependent manner
with an IC50 value of 18.3 ȝM (inhibitor concentration producing 50% inhibition), but does
33
not affect the formation of the active cis 5-thiol metabolite (Wang et al. 2015). Some other
potential inhibitors such as ramipril, perindopril, carvedilol, verapamil, isradipine,
amlodipine, rivastigmine, diclofenac acyl-ȕ-D-glucuronide, clopidogrel
acyl-ȕ-D-glucuronide, ibuprofen acyl-ȕ-D-glucuronide, and naproxen
acyl-ȕ-D-glucuronide have also been identified in vitro using the model substrate PNPA
(Inoue et al. 2013, Tsurkan et al. 2013, Thomsen et al. 2014, Kristensen et al. 2014).
Though numerous drug interactions have been identified using in vitro methods, the
clinical implications of many interactions remain unknown (Laizure et al. 2013). The first
evidence of a clinically significant drug interaction involving a carboxylesterase substrate
was an interaction between cocaine and ethanol (Bourland et al. 1997). CES1 catalyzes the
transesterification of cocaine in the presence of ethanol producing a pharmacologically
active cocaethylene metabolite (benzoylecgonine ethyl ester), which may contribute to the
increased toxicity of cocaine (Brzezinski et al. 1994).
A metabolic interaction between methylphenidate and ethanol was first reported in
1999, when the transesterification product ethylphenidate was found in blood samples from
two suicide overdoses (Markowitz et al. 1999). Ethanol inhibits the CES1-mediated
hydrolysis of methylphenidate, resulting in increased methylphenidate exposure (Parker et
al. 2015). The peak plasma concentration (Cmax) and the area under the plasma
concentration-time curve (AUC) of methylphenidate increased by 40% and 25% (Patrick
et al. 2007). Ethanol co-administration also significantly inhibits oseltamivir hydrolysis to
oseltamivir carboxylate, resulting in increased exposure to parent oseltamivir (Parker et al.
2015). The oseltamivir AUC0-6h increased by 27% and the oseltamivir carboxylate to
oseltamivir AUC0-6h ratio decreased by 34% (Parker et al. 2015). The systemic exposure to
the oseltamivir carboxylate was, however, not reduced (Parker et al. 2015).
In line with the in vitro observed interaction between ACE inhibitors and clopidogrel,
co-treatment with trandolapril or enalapril and clopidogrel is associated with increased
bleeding risk in patients after myocardial infarction. Hazard ratios for clinically significant
bleeding in ACE inhibitor-treated patients cotreated with or without clopidogrel were 1.10
and 0.90, as compared with patients who did not receive ACE inhibitors (Kristensen et al.
2014). Even though clopidogrel might inhibit the CES1-mediated activation of ramipril or
perindopril, their concomitant use was not associated with an elevated risk of recurrent
myocardial infarction, heart failure, or death in one study (Cressman et al. 2015).
Table 4. Drugs, drug metabolites, and other compounds that are CES1 inhibitors.
Inhibitor Ki IC50 Test system Substrate Cmax **
(Dose)
References
Aripiprazole 61.7μM s9 fraction Methylphenidate 0.07μM
(6mg)
Kubo et al. 2007,
Zhu et al. 2010
Clopidogrel 5μM rCES1 Oseltamivir 0.01μM
(600mg)
Shi et al. 2006,
Tarkiainen et al.
2015a
Clopidogrel * * HLM, rCES1 Oxybutynin 0.01μM
(600mg)
Sato et al. 2012,
Tarkiainen et al.
2015a
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Digitonin 25.8μM rCES1 Lidocaine n/a Shimizu et al. 2014
Diltiazem 9.0μM rCES1 Trandolapril 0.1μM
(60 mg)
Caille et al. 1991,
Thomsen et al.
2014
Enalapril * * s9 fraction Clopidogrel 0.23μM
(10mg)
Kristensen et al.
2014,
Tarkiainen et al.
2015b
Ethanol * * s9 fraction Clopidogrel 20mM
(55g)
Jones 1984,
Tang et al. 2006
Ethanol 23mM rCES1 Oseltamivir 20mM
(55g)
Jones 1984,
Parker et al. 2015
Fluoxetine 58.9μM s9 fraction Methylphenidate 0.04μM
(20mg)
Zhu et al. 2010,
Shi et al. 2010
Loperamide 0.44mM rCES1 Capecitabine 0.01μM
(16mg)
Doser et al. 1995,
Quinney et al.
2005
Nelfinavir 6.6μM s9 fraction Methylphenidate 5.6μM
(800mg)
Kaldor et al. 1997,
Rhoades et al.
2012
Nitrendipine 1.1μM rCES1 Imidapril 0.1μM
(20mg)
Kirch et al. 1984,
Yanjiao et al. 2013
Nitrendipine 1.2μM HLM Imidapril 0.1μM
(20mg)
Kirch et al. 1984,
Yanjiao et al. 2013
Perphenazine 65.0μM s9 fraction Methylphenidate 2.2nM
(7mg)
Özdemir et al.
1997,
Zhu et al. 2010
Physostigmine * * HLM Irinotecan 0.6nM
(2mg)
Walter et al. 1995,
Slatter et al. 1997
Procainamide 29.3μM HLM Imidapril 0.02μM
(1000mg)
Martin et al. 1996,
Takahashi et al.
2009
Procainamide * * Human liver
homogenate
Meperidine 0.02μM
(1000mg)
Martin et al. 1996,
Bailey & Briggs
2003
Quinidine * * Human liver
homogenate
Meperidine 6.7μM
(250mg)
Rao & Rambhau
1995,
Bailey & Briggs
2003
Simvastatin
(lactone)
18.3μM s9 fraction Clopidogrel 0.02μM
(40mg)
Keskitalo et al.
2009,
Wang et al. 2015
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Simvastatin
(lactone)
0.1μM rCES1 Imidapril 0.02μM
(40mg)
Keskitalo et al.
2009,
Fukami et al. 2010
Simvastatin
(lactone)
0.8μM HLM Imidapril 0.02μM
(40mg)
Keskitalo et al.
2009,
Fukami et al. 2010
Telmisartan 0.5μM rCES1 Imidapril 0.3μM
(40mg)
Zhang et al. 2006,
Yanjiao et al. 2013
Telmisartan 1.7μM HLM Imidapril 0.3μM
(40mg)
Zhang et al. 2006,
Yanjiao et al. 2013
Thioridazine 58.3μM s9 fraction Methylphenidate 1.0μM
(100mg)
Chakraborty et al.
1989,
Zhu et al. 2010
Troglitazone 0.6μM rCES1 Imidapril 2.7μM
(400mg)
Ott et al. 1998,
Fukami et al. 2010
Troglitazone 5.6μM HLM Imidapril 2.7μM
(400mg)
Ott et al. 1998,
Fukami et al. 2010
Valproate 2.5mM HLM Rufinamide 0.2μM
(300mg)
Rha et al. 1993,
Williams et al.
2011b
Verapamil 16.0μM rCES1 Trandolapril 0.1μM
(80mg)
McAllister &
Kirsten 1982,
Thomsen et al.
2014
* Ki or IC50 values not reported.
** Oral dose.
CES1, carboxylesterase 1; CES2, carboxylesterase 2; HLM, human liver microsome; HJM, human
jejunum microsome; IC50, inhibitor concentration producing 50% inhibition; Ki, inhibition constant;
n/a, not available; rCES1, recombinant carboxylesterase 1; rCES2, recombinant carboxylesterase
2.
2.3.6 Physiological role
In addition to its role in xenobiotic metabolism, CES1 has been shown to catalyze reactions
involved in cholesterol homeostasis and fatty acid metabolism (Satoh & Hosokawa 1998,
Fleming et al. 2005). CES1 possesses acyl-coenzyme A:cholesterol acyltransferase
(ACAT) activity, which generates cholesterol esters from fatty-acyl coenzyme A and free
cholesterol (Becker et al. 1994, Bencharit et al. 2003, Fleming et al. 2005). It has been also
found to catalyze the reverse reaction, acting as a cholesterol ester hydrolase (CEH)
(Bencharit et al. 2003, Redinbo et al. 2003, Fleming et al. 2005). These actions are
important for cholesterol trafficking both within cells and between tissues throughout the
body (Bencharit et al. 2003). For example, overexpression of CES1 in vitro induces the
efflux of cholesterol from the cell (Ghosh & Natarajan 2001, Redinbo et al. 2003).
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Furthermore, CES1 can produce fatty acid ethyl esters (FAEEs) via the transesterification
of short-chain and long-chain fatty acids with ethanol (Fleming et al. 2005, Friedrichsen et
al. 2013).
CES1 appears to be critical to protein retention and release from the ER (Bencharit et
al. 2003, Redinbo et al. 2003). It contains ER targeting and retention sequences at its N and
C termini and associates with the ER lumen (Bencharit et al. 2003). CES1 also complexes
with the UGTs to hold them in the ER lumen (Bencharit et al. 2003) and is involved in
binding to and retaining the C-reactive protein (CRP) in the ER lumen of human
hepatocytes before its release into the plasma (Yue et al. 1996, Bencharit et al. 2003,
Redinbo et al. 2003). Reduction in CES1 affinity for CRP is accountable for the release of
CRP at levels up to 1000-fold higher than normal (Macintyre et al. 1994, Satoh &
Hosokawa 1998, Redinbo et al. 2003). CRP responds to infection and cellular damage
throughout the body and is a highly sensitive early marker for the development of
atherosclerosis (Labarrere et al. 2002, Bencharit et al. 2003, Redinbo et al. 2003).
In addition, CES1 seems to have a role in hepatitis C virus (HCV) replication,
translation, and virion release (Blais et al. 2010). The knockdown of CES1 with small
interfering RNA resulted in lower levels of HCV replication and correspondingly
upregulation of CES1 favored HCV propagation (Blais et al. 2010).
2.4 Other carboxylesterases
Carboxylesterase 2. The CES2 gene contains 12 exons and spans about 11 kb (Wu et al.
2003, Marsh et al. 2004). It lies approximately 11 Mb downstream from the CES1 gene
(Marsh et al. 2004). The close proximity and homology (73% coding region homology and
48% amino acid sequence homology) of these genes imply an ancestral gene duplication
event at this chromosomal region (Marsh et al. 2004, Staudinger et al. 2010). CES2 has
three transcription start sites at -74, -629, and -1187, all of which are transcriptionally active
in HepG2 cells (Wu et al. 2003). CES2 appears to have very little genetic variation, with
the majority of SNVs occurring in intronic regions (Marsh et al. 2004).
CES2 is expressed in the small intestine, colon, kidney, spleen, liver, heart, brain, and
testis and is essentially absent in all other organs (Schwer et al. 1997, Xu et al. 2002, Satoh
et al. 2002, Imai 2006, Kuhl et al. 2016). Duodenal and jejunal CES2 expression levels
correlate with each other, but not with the hepatic expression levels (Imai & Ohura 2010,
Chen et al. 2015). In the kidney, CES2 contributes to about 95% of the hydrolytic activity
(Hatfield et al. 2011). CES2 is an about 60 kDa monomer (Pindel et al. 1997, Imai & Ohura
2010, Fukami & Yokoi 2012) and its catalytic triad consists of serine (228), glutamic acid
(345), and histidine (457) (Schiel et al. 2007).
The preferential substrates for CES2 are compounds esterified with relatively large
alcohol moieties (Table 5) (Satoh et al. 2002, Imai 2006, Laizure et al. 2013). The most
investigated CES2 substrate is irinotecan (CPT-11), a topoisomerase I inhibitor used for
the treatment of a variety of malignancies. CES2 catalyzes the hydrolysis of irinotecan to
its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), which is further
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metabolized to an inactive glucuronide metabolite (SN-38G) (Humerickhouse et al. 2000).
Irinotecan appears to be ineffective in tumors lacking CES2 expression, such as
lymphomas, suggesting that local CES2 expression in tumors may influence treatment
outcome (Schiel et al. 2007). Interestingly, it is overexpressed in pancreatic ductal
adenocarcinoma tissue both at the mRNA and protein level and its overexpression
associates with a longer overall survival (Capello et al. 2015). CES2 also hydrolyzes
several cardiovascular drugs, such as candesartan cilexetil and simvastatin, and antiplatelet
drugs, such as acetylsalicylic acid and prasugrel (Williams et al. 2008, Laizure et al. 2013).
In vitro, telmisartan, vinblastine, diltiazem, and verapamil inhibit the hydrolysis of
irinotecan (Table 6) (Yanjiao et al. 2013, Shimizu et al. 2014). The hydrolytic activity of
recombinant CES2 is also inhibited by timolol, cilnidipine, simvastatin, lovastatin, and
fenofibrate (Fukami et al. 2010, Yanjiao et al. 2013). In human liver microsomes, orlistat
inhibits the hydrolysis of the model substrate PNPA (Xiao et al. 2013).
Table 5. Drugs that are metabolized by CES2.
Substrate Therapeutic use
and/or drug class
Hydrolysis
product
(activity)
Other
metabolizing
enzymes
References
6-monoacetyl-
morphine
Heroin metabolite Morphine
(active)
Dean et al. 1991,
Brzezinski et al. 1997,
Hatfield et al. 2010
Acetylsalicylic
acid
Antiplatelet,
analgesic
Salicylate
(active)
Takai et al. 1997,
Tang et al. 2006
Capecitabine Oncologic 5’-deoxy-5-
fluorocytidine
(inactive)
CES1
CDA
TP
UPP1
UPP2
Quinney et al. 2005
Candesartan
cilexetil
Antihypertensive,
angiotensin II
receptor blocker
Candesartan
(active)
CES1
CMBL
Ishizuka et al. 2013
Cocaine Analgesic Ecgonine methyl
ester
(inactive)
CES2
BChE
Brzezinski et al. 1994
Dabigatran
etexilate
Anticoagulant Dabigatran
(active)
CES1 Laizure et al. 2014
Flutamide Oncologic 5-amino-2-nitro-
benzotrifluoride
(inactive)
CYP1A2
CYP3A4
AADAC
Kobayashi et al. 2012
Heroin Analgesic 6-monoacetyl-
morphine
(active)
CES1
BChE
Dean et al. 1991,
Brzezinski et al. 1997,
Hatfield et al. 2010
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Irinotecan
(CPT-11)
Oncologic 7-ethyl-10-
hydroxycampto-
thecin
(SN-38)
(active)
CES1
UGT1A1
UGT1A7
UGT1A9
CYP3A4
CYP3A5
Takai et al. 1997,
Humerickhouse et al.
2000
Mycophenolate
mofetil
Immunosuppressant Mycophenolate
(active)
CES1 Fujiyama et al. 2010
Olmesartan
medoxomil
Antihypertensive,
angiotensin II
receptor blocker
Olmesartan
(active)
CES1
CMBL
Ishizuka et al. 2010
Oxybutynin Antispasmodic,
incontinence
2-cyclohexyl-2-
phenylglycolic
acid
(inactive)
CES1
CYP4A4
Takai et al. 1997
Prasugrel Antiplatelet Thiolactone
metabolite
(inactive)
CYP3A
CYP2B6
AADAC
Williams et al. 2008,
Kurokawa et al. 2016
Simvastatin Antihyperlipidemic Dihydroxy acid
metabolite
(active)
CES1
CYP3A4
Vickers et al. 1990,
Parker & Laizure
2010
AADAC, arylacetamide deacetylase; BChE, butyrylcholinesterase; CDA, cytidine deaminase;
CES1, carboxylesterase 1; CMBL, carboxymethylenebutenoledase; CYP, cytochrome P450; TP,
thymidine phosphorylase; UPP1, uridine phosphorylase 1; UPP2, uridine phosphorylase 2; UGT,
uridine 5´-phosphate glucuronosyltransferase.
Table 6. Drugs, drug metabolites, and other compounds that are CES2 inhibitors.
Inhibitor Ki IC50 Test system Substrate Cmax **
(Dose)
References
Clopidogrel 50μM rCES2 Oxybutynin 0.01μM
(600mg)
Sato et al. 2012,
Tarkiainen et al.
2015a
Diltiazem 0.3μM rCES2 Irinotecan 0.1μM
(60mg)
Caille et al. 1991,
Yanjiao et al. 2013
Diltiazem 2.9μM HLM Irinotecan 0.1μM
(60mg)
Caille et al. 1991,
Yanjiao et al. 2013
Diltiazem 4.7μM HJM Irinotecan 0.1μM
(60mg)
Caille et al. 1991,
Yanjiao et al. 2013
Fenofibrate 0.04μM rCES2 Irinotecan 13.3μM
(160mg)
Jones et al. 2004,
Fukami et al. 2010
Fenofibrate 87.7μM HLM Irinotecan 13.3μM
(160mg)
Jones et al. 2004,
Fukami et al. 2010
Fenofibrate 0.5μM HJM Irinotecan 13.3μM
(160mg)
Jones et al. 2004,
Fukami et al. 2010
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Loperamide * * Human liver
homogenate
6-acetyl-
morphine
0.01μM
(16mg)
Doser et al. 1995,
Andersson et al. 2015
Loperamide * * HJM Flutamide 0.01μM
(16mg)
Doser et al. 1995,
Kobayashi et al. 2012
Loperamide 5μM rCES2 Oxybutynin 0.01μM
(16mg)
Doser et al. 1995,
Sato et al. 2012
Physostigmine * * HLM Irinotecan 0.6μM
(2mg)
Walter et al. 1995,
Slatter et al. 1997
Physostigmine 3.μM HJM Irinotecan 0.6μM
(2mg)
Walter et al. 1995,
Takahashi et al. 2009
Simvastatin
(lactone)
0.7μM rCES2 Irinotecan 0.02μM
(40mg)
Keskitalo et al. 2009,
Fukami et al. 2010
Simvastatin
(lactone)
1.9μM HLM Irinotecan 0.02μM
(40mg)
Keskitalo et al. 2009,
Fukami et al. 2010
Simvastatin
(lactone)
3.7μM HJM Irinotecan 0.02μM
(40mg)
Keskitalo et al. 2009,
Fukami et al. 2010
Telmisartan 0.4μM rCES2 Irinotecan 0.3μM
(40mg)
Zhang et al. 2006,
Shimizu et al. 2014
Telmisartan 0.5μM HLM Irinotecan 0.3μM
(40mg)
Zhang et al. 2006,
Shimizu et al. 2014
Verapamil 3.8μM rCES2 Irinotecan 0.1μM
(80mg)
McAllister & Kirsten
1982,
Yanjiao et al. 2013
Verapamil 11.5μM HLM Irinotecan 0.1μM
(80mg)
McAllister & Kirsten
1982,
Yanjiao et al. 2013
Verapamil 15.8μM HJM Irinotecan 0.1μM
(80mg)
McAllister & Kirsten
1982,
Yanjiao et al. 2013
Vinblastine 37.4μM HLM Irinotecan 0.01μM
(3mg/m2)
Chong et al. 1988,
Shimizu et al. 2014
Vinblastine 2.0μM rCES2 Irinotecan 0.01μM
(3mg/m2)
Chong et al. 1988,
Shimizu et al. 2014
* Ki or IC50 values not reported.
** Oral dose, except for vinblastine which is admistered IV.
CES1, carboxylesterase 1; CES2, carboxylesterase 2; HLM, human liver microsome; HJM, human
jejunum microsome; IC50, inhibitor concentration producing 50% inhibition; IV, intravenously; Ki,
inhibition constant; rCES1, recombinant carboxylesterase 1; rCES2, recombinant carboxylesterase
2.
Carboxylesterases 3, 4, and 5. CES3 is expressed in the liver, brain, and colon, but at
markedly lower levels than CES1 and CES2 (Sanghani et al. 2004, Sun et al. 2004, Imai
2006, Williams et al. 2011a). CES3 is more highly expressed in brain endothelial cells than
in the liver and has been suggested to function at the blood-brain barrier (Walter Soria et
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al. 2010). In vitro, CES3 participates in the hydrolysis of irinotecan, but its catalytic
efficiency is markedly lower than those of CES1 and CES2 (Sanghani et al. 2004).
Little is known about the expression of CES4 and CES5 in humans. They are apparently
expressed in the brain (Holmes et al. 2010) but their metabolic roles are not yet known
(Holmes et al. 2010).
2.5 Other esterases
Esterases can be divided into three categories according to the Aldridge esterase
classification (Aldridge 1953). Esterases that efficiently hydrolyze organophosphates and
require an inorganic ion as a cofactor are classified as A-esterases, such as paraoxonases
(Staudinger et al. 2010, Williams et al. 2011b). Esterases that are inhibited by
organophosphates, carbamates, and organosulphur compounds are classified as B-
esterases, such as carboxylesterases (Satoh & Hosokawa 2006, Staudinger et al. 2010).
Esterases that do not hydrolyze organophosphates and are inhibited by them are classified
as C-esterases, such as carboxymethylenebutenoledase (Staudinger et al. 2010). In
addition, multiple other enzymes such as carboxypeptidase A, aldehyde dehydrogenase,
carbonic anhydrases B and C, lipase, trypsin, and CYPs have esterase activity and could
contribute to the biotransformation of ester-based prodrugs (Liederer & Borchardt 2006).
Characteristically, carboxylic acid ester hydrolysis by CYPs leads to an aldehyde and an
acid rather than an alcohol and an acid (Liederer & Borchardt 2006).
Albumin. Albumin is abundantly present in plasma and extracellular fluids (Bahar et al.
2012). Although albumin is a carrier protein rather than an esterase, it reportedly has
esterase-like activity with some substrates, such as PNPA and acetylsalicylic acid (Liederer
& Borchardt 2006, Bahar et al. 2012). The hydrolytic activity of albumin is significantly
lower than that of carboxylesterases, and typically it contributes to less than 20% of the
overall esterase activity (Liederer & Borchardt 2006, Bahar et al. 2012).
Acetylcholinesterase. Acetylcholinesterase (AChE) rapidly hydrolyzes the
neurotransmitter acetylcholine at cholinergic synapses and neuromuscular junctions
(Liederer & Borchardt 2006), as well as some esters, amides, and anilides (Liederer &
Borchardt 2006). Depending on its molecular form, AChE is present mainly in the brain
and red blood cells and at neuromuscular junctions (Li et al. 2005, Liederer & Borchardt
2006, Bahar et al. 2012).
Arylacetamide deacetylase. Arylacetamide deacetylase (AADAC) is a microsomal serine
esterase that is expressed in the liver and gastrointestinal tissues at both the mRNA and
protein expression levels (Fukami & Yokoi 2012, Oda et al. 2015).  AADAC is localized
on the luminal side of the ER, similar to carboxylesterases (Shimizu et al. 2014). It was
first identified as the enzyme that catalyzes the deacetylation of the carcinogen
2-acetylaminofluorene (Fukami & Yokoi 2012), but it also hydrolyzes flutamide,
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phenacetin, indiplon, rifamycins, and prasugrel (Fukami & Yokoi 2012, Kurokawa et al.
2016). The AADAC-mediated hydrolysis of flutamide is associated with hepatotoxicity and
nephrotoxicity and that of phenacetin with hematologic toxicities (Shimizu et al. 2014).
Butyrylcholinesterase. Butyrylcholinesterase (BChE, also known as
pseudocholinesterase) is present in plasma as well as the rough ER of various tissues, such
as liver, lung, brain, muscle, pancreas, and kidney (Liederer & Borchardt 2006, Fukami &
Yokoi 2012, Oda et al. 2015), although the enzyme activity was undetectable in the liver
(Shimizu et al. 2014). The physiological function of BChE is not completely understood.
In the absence of BChE no harmful physiological effects are observed (Liederer &
Borchardt 2006). Several drugs, such as succinylcholine, mivacurium, cocaine, and heroine
are substrates of BChE (Fukami & Yokoi 2012). Inherited deficiency of BChE leads to
prolonged succinylcholine-induced paralysis and apnea, for up to 3-4 hours instead of the
usual 5-15 minutes (Gardiner & Begg 2006).
Carboxymethylenebutenoledase. Carboxymethylenebutenoledase (CMBL) is
predominantly expressed in the liver, intestine, and kidney (Ishizuka et al. 2013). CMBL
hydrolyzes olmesartan medoxomil to its active metabolite olmesartan (Fukami & Yokoi
2012, Ishizuka et al. 2013).
Paraoxonases. Paraoxonases (PONs, also known as arylesterases) have a catalytic dyad
consisting of two histidine residues (at positions 115 and 134), which are activated by the
binding of divalent calcium (Bahar et al. 2012). PON1 is expressed in the liver and plasma
and it plays a role in the lipid transfer and assembly of very low density lipoproteins
(VLDLs) (Liederer & Borchardt 2006). PON2 is ubiquitously expressed in human tissues,
except plasma (Oda et al. 2015). PON3 is expressed in the liver and plasma (Liederer &
Borchardt 2006). PON1 and PON3 are the main plasma esterases responsible for the
hydrolysis of pesticides possessing an aryl group or organophosphorus esters, such as
paraoxon, sarin, and soman (Bahar et al. 2012). PONs also catalyze the hydrolysis of a
broad spectrum of compounds such as aromatic carboxylic acid esters, lactones, and cyclic
carbonates (Satoh et al. 2002, Liederer & Borchardt 2006). Several drugs, including
pilocarpine, simvastatin, lovastatin, and spironolactone are hydrolyzed by PON1 and
PON3, whereas seemingly no drugs are hydrolyzed by PON2 (Satoh et al. 2002, Oda et al.
2015). Phenobarbital and mercurial compounds increase paraoxonase activity while
smoking decreases paraoxonase activity (Liederer & Borchardt 2006).
Valacyclovir hydrolase. Valacyclovir hydrolase (also known as valacyclovirase and
biphenyl hydrolase-like protein) is an Į-amino acid ester hydrolase and highly effective in
catalyzing the hydrolysis of valacyclovir to the active antiviral drug acyclovir (Liederer &
Borchardt 2006, Lai et al. 2008). Otherwise, valacyclovir hydrolase shows relatively low
activity towards characteristic substrates of the serine esterases, and its physiological role
is unknown (Liederer & Borchardt 2006). Valacyclovir hydrolase is expressed in the liver,
kidney, heart, intestine, and skeletal muscle (Kim et al. 2004).
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2.6 Drugs studied
2.6.1 Oseltamivir
Oseltamivir (C16H28N2O4, 312.40 g/mol) is widely used in the treatment and prophylaxis
of influenza A and B virus infections. Oseltamivir reduces the duration and severity of
influenza (Widmer et al. 2010). It is an ethyl ester prodrug that is rapidly hydrolyzed in the
liver to active oseltamivir carboxylate by CES1 (Figure 5), no other metabolites have been
identified. The active metabolite oseltamivir carboxylate exerts its antiviral effects via
inhibition of the viral surface glycoprotein neuraminidase (Massarella et al. 2000, Davies
2010). Neuraminidase is the enzyme responsible for the release of newly formed viral
particles from the surface of infected cells, and it increases the mobility of the virus through
the mucus of the respiratory tract (Massarella et al. 2000, Widmer et al. 2010). Since
replication of the influenza virus in the respiratory tract reaches its peak between 24 and 72
hours after the onset of illness, oseltamivir must be administered as early as possible
(Widmer et al. 2010).
Figure 5. Biotransformation of oseltamivir. CES1, carboxylesterase 1.
The usual dosage of oseltamivir is 75 mg orally twice daily for 5 days. Oseltamivir is
well tolerated at single doses of up to 1000 mg and twice-daily doses of up to 500 mg (He
et al. 1999, Massarella et al. 2000). In clinical trials, approximately 10-20% of patients
reported adverse effects and the most common adverse effects were upper gastrointestinal
disturbances such as nausea, vomiting, and abdominal pain (Widmer et al. 2010). In
adolescents, however, oseltamivir has also been associated with neuropsychiatric reactions
including delirium, behavioral changes, convulsions, and even suicides (Izumi et al. 2007).
Oseltamivir has a relatively high lipophilicity and passive permeability through cell
membranes, although P-glycoprotein (P-gp) transports it from the CNS (Holodniy et al.
2008, Wattanagoon et al. 2009). Oseltamivir carboxylate poorly penetrates the blood-brain
barrier. High concentrations of the parent oseltamivir in plasma may result in increased
concentrations in the CNS and therefore individuals with a reduced P-gp or CES1 activity
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may be at increased risk for neurotoxicity (Izumi et al. 2007, Wattanagoon et al. 2009, Ito
et al. 2017).
Following oral administration, oseltamivir is rapidly absorbed from the gastrointestinal
tract (Davies 2010). The oral bioavailability of oseltamivir is more than 75% (Table 7) (He
et al. 1999, Holodniy et al. 2008). The time to reach peak plasma concentration (tmax) of
oseltamivir carboxylate is about 4 hours, and it is eliminated primarily by renal excretion
that includes glomerular filtration and tubular secretion by organic anion transporters 1 and
3 (OAT1 and OAT3) (He et al. 1999, Massarella et al. 2000, Holodniy et al. 2008).
Approximately 60-70% of an oral dose of oseltamivir is excreted into the urine as the active
metabolite, and less than 5% is excreted as the parent oseltamivir (He et al. 1999). Small
amounts appear in feces (<20%, 50% as oseltamivir and 50% as oseltamivir carboxylate)
(He et al. 1999, Widmer et al. 2010). The elimination half-lifes (t½) of oseltamivir and
oseltamivir carboxylate are about 1-3 hours and 6-10 hours (Davies 2010). Administration
of oseltamivir with food does not significantly affect the Cmax or AUC0- of  the  active
metabolite (Widmer et al. 2010). Also, altered gastric pH, such as induced by antacids, does
not affect the absorption of oseltamivir (He et al. 1999). Oseltamivir carboxylate is
minimally bound to plasma proteins (<3%), compared to the parent oseltamivir
(approximately 42%) (He et al. 1999, Widmer et al. 2010). Plasma concentrations of
oseltamivir and oseltamivir carboxylate are linear and proportional at doses of up to 500
mg twice daily (He et al. 1999, Massarella et al. 2000). Multiple-dose exposure is
predictable from single-dose data, and steady-state plasma concentrations are achieved
within 2-3 days (Massarella et al. 2000).
Children usually express low levels of carboxylesterases and the hydrolysis of
oseltamivir is delayed (oseltamivir carboxylate tmax 6 hours versus 4 hours) in children (1-
2 years) (Shi et al. 2006, Yang et al. 2009, Widmer et al. 2010, Shi et al. 2011). Optimal
exposure to oseltamivir carboxylate is achieved by using adjusted weight-based dosing
(e.g., 3-3.5mg/kg) (Kimberlin et al. 2013). The overall exposures to oseltamivir and
oseltamivir carboxylate at steady state have been approximately 25% larger in elderly
patients than in younger patients, likely due to decreased renal function (Massarella et al.
2000, Widmer et al. 2010). The AUC of oseltamivir carboxylate increases 100%, 200%,
and 1000% in patients who have mild, moderate, and severe renal impairment (He et al.
1999, Widmer et al. 2010), though the increased drug exposure has not been associated
with reduced tolerability (He et al. 1999). In patients with hepatic impairment, the
oseltamivir and oseltamivir carboxylate Cmax values were 6% and 19% lower, and their
AUC values 33% higher and 19% lower than in healthy subjects (Snell et al. 2005). The
oseltamivir carboxylate to oseltamivir AUC ratio was also slightly lower in patients with
hepatic impairment (Snell et al. 2005).
Oseltamivir and oseltamivir carboxylate are not substrates of and do not interact with
CYPs or UGTs. Therefore, no drug-interactions are expected to occur via these metabolic
pathways (He et al. 1999, Widmer et al. 2010). The low protein binding of both compounds
also suggests that drug interactions involving displacement from proteins are unlikely (He
et al. 1999). Oseltamivir is a substrate of peptide transporter 1 (PEPT1, SLC15A1) and P-gp
(ABCB1), the latter of which could limit its absorption from the gastrointestinal tract
(Widmer et al. 2010). The OAT1 inhibitor probenicid effectively inhibits the renal
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excretion of oseltamivir, increasing the AUC of oseltamivir carboxylate by 150% and
decreasing its renal clearance by 30-50% (He et al. 1999, Holodniy et al. 2008,
Wattanagoon et al. 2009). In vitro, the antiplatelet drug clopidogrel inhibits the hydrolysis
of oseltamivir by as much as 90% when assayed at equal concentrations (Shi et al. 2006),
though the assessed drug concentrations were hundreds of times higher than those observed
in clinical use. Dexamethasone slightly reduced the AUC of oseltamivir carboxylate and
increased the renal clearance of oseltamivir, but the interaction was not clinically
significant (Jang et al. 2017). Coadministration of oseltamivir with paracetamol, aspirin,
cimetidine, and amoxicillin had no clinically significant effect on the pharmacokinetics of
these compounds or oseltamivir itself (Hill et al. 2002, Oo et al. 2002, Snell et al. 2002,
Davies 2010).
2.6.2 Clopidogrel
Clopidogrel (C16H16ClNO2S, 321.81 g/mol) is widely used in the treatment and prophylaxis
of atherothrombotic and thromboembolic diseases, such as stroke and myocardial
infarction. It is a thienopyridine prodrug that is converted to a pharmacologically active cis
5-thiol metabolite through an inactive intermediate 2-oxo-clopidogrel, catalyzed by CYP
enzymes, mainly CYP2C19, CYP3As, CYP2B6, CYP1A2, and CYP2C9 (Figure 6) (Farid
et al. 2010, Dansette et al. 2012). The active cis 5-thiol metabolite irreversibly binds to the
platelet P2Y12 subtype of the ADP receptor and thereby inhibiting aggregation (Mills et al.
1992). About 90% of the absorbed clopidogrel is, however, rapidly hydrolyzed by CES1 to
an inactive carboxylic acid metabolite, which is further metabolized by glucuronidation
(Caplain et al. 1999, Lins et al. 1999, Tang et al. 2006, Hagihara et al. 2009, Silvestro et
al. 2011). In addition, CES1 hydrolyzes 2-oxo-clopidogrel and the active metabolite to their
corresponding carboxylic acid derivatives (Hagihara et al. 2009). Ultimately, only a small
proportion of clopidogrel is converted to the active metabolite (Farid et al. 2010).
45
Figure 6. Biotransformation pathways of clopidogrel. CES1, carboxylesterase 1; CYP,
cytochrome P 450; UGT, uridine 5´-diphosphate glucuronosyltransferase.
Marked interindividual variability exists in the pharmacokinetics, platelet inhibitory
effects, and clinical efficacy of clopidogrel (Caplain et al. 1999, Gurbel et al. 2003,
Matetzky et al. 2004, Cuisset et al. 2006). A significant percentage (5-40%) of individuals
treated with clopidogrel do not receive the anticipated therapeutic benefit, which is
associated with an increased risk of adverse outcomes (Zhu et al. 2013). Mechanisms of
variability in the pharmacodynamics of clopidogrel are likely due to several factors
including poor compliance to treatment, variable absorption of the prodrug, variable
clearance of the active metabolite, drug-drug interactions, and ability of thrombin to bypass
complete ADP-inhibition and still induce platelet aggregation (Malinin et al. 2007). The
P2Y12 receptor variability, genetic polymorphisms of platelet receptors, and differences in
platelet signal transduction pathways may also contribute to variability in clopidogrel
response (Malinin et al. 2007).
Genetic factors explain an estimated 70% of the interindividual variance in clopidogrel
pharmacokinetics and pharmacodynamics (Shuldiner et al. 2009). In particular, the
loss-of-function of CYP2C19 c.681G>A (*2, rs4244285) and c.636G>A (*3, rs4986893)
SNVs impair clopidogrel bioactivation and efficacy (Kim et al. 2008, Simon et al. 2009,
Mega et al. 2009, Scott et al. 2011, Scott et al. 2013, Samant et al 2017, Backman et al
2017). Carriers of the CYP2C19*2 allele show lower active metabolite levels, higher
platelet reactivity, and poorer outcomes (Windecker et al. 2014). CYP2C19 loss-of-
function alleles account for about 12% of the variability in clopidogrel response (Shuldiner
et al. 2009). Some studies implicate variants in other genes associated with clopidogrel
response (e.g., ABCB1, CES1, CYP2B6, CYP2C9, P2Y12, and PON1) (Scott et al. 2011).
The usual dosage of clopidogrel is 75 mg once daily. A loading dose of 300-600 mg
reduces the time required to achieve maximal platelet aggregation inhibition (Jarvis &
46
Simpson 2000, Windecker et al. 2014), and is therefore recommended if rapid onset of the
antiplatelet effect is needed, such as before percutaneous coronary intervention (PCI). The
effect of 75 mg daily doses of clopidogrel on platelet aggregation typically reaches a steady
state within 3 to 7 days (Farid et al. 2010). The most common adverse effects are
gastrointestinal bleeding, headache, abdominal pain, rash, dizziness, dyspepsia, diarrhea,
pruritus, constipation, vertigo, gastritis, ulcer, and hemorrhage, each occurring in less than
8% of patients (Jarvis & Simpson 2000). During postmarketing surveillance of clopidogrel,
hypersensitivity reactions, including angioedema, bronchospasm, anaphylactoid reactions,
arthritis, and thrombotic thrombocytopenic purpura have been reported (Jarvis & Simpson
2000, Balamuthusamy & Arora 2007, Beavers et al. 2015).
The bioavailability of clopidogrel is approximately 50% (Table 7) (Jarvis & Simpson
2000). In vitro, P-gp limits the uptake of clopidogrel, suggesting that P-gp may affect the
intestinal absorption and oral bioavailability of clopidogrel (Jiang et al. 2015). Very low
levels of the inactive parent clopidogrel are present after oral administration of clopidogrel,
since it is rapidly metabolized in the liver (Jarvis & Simpson 2000). The tmax of the main
inactive metabolite of clopidogrel, clopidogrel carboxylic acid, is about 1 hour and the t½
about 7-8 hours (Caplain et al. 1999). About 50% of clopidogrel dose is excreted into the
urine and about 46% into feces, presumably as metabolites (Lins et al. 1999). The renal
clearance (Clrenal) of clopidogrel is approximately 0.25 l/h (Caplain et al. 1999).
Administration with food does not significantly affect the pharmacokinetics or
pharmacodynamics of clopidogrel (Jarvis & Simpson 2000). The exposure to clopidogrel
metabolites increase in a dose-dependent, but less than dose-proportional manner, likely
due to saturable absorption, metabolism, or both (Farid et al. 2010). Clopidogrel and its
carboxylic acid metabolite are 98% and 94% bound to plasma proteins (Farid et al. 2010).
Plasma concentrations of clopidogrel carboxylic acid were higher in the elderly than in
young patients, but this does not appear to be of clinical relevance since bleeding times
remained unaffected (Jarvis & Simpson 2000). Exposure to clopidogrel carboxylic acid was
lower in patients with severe versus moderate renal dysfunction (Jarvis & Simpson 2000).
Mild to moderate hepatic impairment slowed the clopidogrel metabolite formation (Jarvis
& Simpson 2000).
Since the pharmacological effect of clopidogrel is closely linked to its bioactivation via
CYPs, other concomitant medications or food constituents that suppress the activity of
relevant CYPs (e.g., CYP2C19, CYP3As, CYP2C9, CYP2B6, or CYP1A2) may interrupt
the antiplatelet activity of clopidogrel and thus negatively impact the clinical outcome
(Jiang et al. 2015). For example, grapefruit juice impairs the bioactivation and antiplatelet
effects of clopidogrel by inhibiting CYP3A4 and CYP2C19. Grapefruit juice reduced the
Cmax and  AUC0-3h of the active cis 5-thiol metabolite by more than 80% and markedly
decreased the antiplatelet effect of clopidogrel (Holmberg et al. 2014). It has also been
shown, that concomitant use of omeprazole and ketoconazole with clopidogrel reduces the
bioactivation and antiplatelet effect of clopidogrel (Farid et al. 2007, Gilard et al. 2008,
Zahno et al. 2010, Angiolillo et al. 2011). In addition, treatment with CES1-inhibiting ACE
inhibitors may increase bleeding risk in clopidogrel-treated patients (Kristensen et al. 2014,
Cressman et al. 2015). Clopidogrel acyl-ȕ-D-glucuronide is a potent time-dependent
inhibitor of CYP2C8 (Tornio et al. 2014). In a crossover study with 9 healthy volunteers,
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the AUC0- of repaglinide was increased by 5-fold with a 300-mg loading dose of
clopidogrel and by 4-fold with continued daily administration of 75 mg clopidogrel (Tornio
et al. 2014). In vitro, clopidogrel reduces the hydrolytic efficiency of CES1 (Shi et al.
2006).
2.6.3 Quinapril and enalapril
The ACE inhibitors quinapril (C25H30N2O5, 438.52 g/mol) and enalapril (C20H28N2O5,
376.45 g/mol) are widely used in the treatment of hypertension and congestive heart failure.
Both are ethyl ester prodrugs that are rapidly hydrolyzed in the liver to the active diacid
metabolites, quinaprilat and enalaprilat (Klutchko et al. 1986, Todd & Heel 1986). This
bioactivation is catalyzed mainly by CES1 (Figure 7) (Takai et al. 1997, Thomsen et al.
2014). Parent quinapril and enalapril are relatively weak inhibitors of ACE. The active
metabolites quinaprilat and enalaprilat are, however, potent inhibitors of ACE thereby
preventing the conversion of angiotensin I to the vasoactive peptide angiotensin II. These
effects are mediated by binding to both tissue and plasma ACE (Kaplan et al. 1989, Culy
& Jarvis 2002).
Figure 7. Biotransformations of quinapril and enalapril. CES1, carboxylesterase 1.
Large interindividual differences in the effects of ACE inhibitors on blood pressure and
the renin-angiotensin system exist, particularly after the first dose. Several studies have
investigated the effects of genetic variants on the pharmacodynamics of ACE inhibitors
(Hingorani et al. 1995, Todd et al. 1995, Voors et al. 2004, Hannila-Handelberg et al.
2010). For example, some studies show an association of variants in ACE, angiotensinogen,
angiotensin receptor 1, and Į-adducin 1 with a response to ACE inhibitors (Arnett et al.
2006). In addition, polymorphisms in the SLCO1B1 gene, encoding the hepatic influx
48
transporter organic anion-transporting polypeptide 1B1 (OATP1B1), may influence the
pharmacokinetics of enalapril and temocapril (Maeda et al. 2006, Niemi et al. 2011, Tian
et al. 2011).
The usual, generally well tolerated, dosage of quinapril and enalapril is 5-40 mg orally
once a day (McFate Smith et al. 1984, Culy & Jarvis 2002). The most common adverse
effects are dizziness, headache, cough, fatigue, nausea, and vomiting, each occurring in less
than 8% of patients (Irvin & Viau 1986, Frank et al. 1989, Culy & Jarvis 2002).
Angioedema has been seen in 0.1% of patients using quinapril or enalapril (Culy & Jarvis
2002).
Following oral administration, quinapril and enalapril are hydrolyzed to the active
diacid metabolites, quinaprilat (about 40% of an oral dose) and enalaprilat (about 60% of
an oral dose) (Table 7) (Davies et al. 1984, Kaplan et al. 1989, Olson et al. 1989, Wadworth
& Brogden 1991, MacFadyen et al. 1993). Quinapril also has two minor inactive
diketopiperazine metabolites (Olson et al. 1989, Wadworth & Brogden 1991), but enalapril
has no further metabolites (Todd & Heel 1986). The tmax of quinaprilat and enalaprilat is
about 2 hours and 2-4 hours, and they are eliminated primarily by renal excretion with
elimination half-lifes of about 2 hours and 2-6 hours (Todd & Heel 1986, Olson et al. 1989,
Kaplan et al. 1989, MacFadyen et al. 1993). Quinaprilat and enalaprilat have long terminal
elimination half-lives (about 25 hours and 36 hours), likely because of slow release of
quinaprilat and enalaprilat from ACE (MacFadyen et al. 1993, Culy & Jarvis 2002).
Approximately 30-40% of an oral dose of quinapril and enalapril is excreted into the urine
as the active metabolites (Ulm 1983, Todd & Heel 1986, Olson et al. 1989). The remainder
of quinapril and approximately 30% of enalapril are eliminated in the feces as unabsorbed
parent prodrugs or by biliary excretion of parent prodrugs and their metabolites (Todd &
Heel 1986, Olson et al. 1989). The Clrenal of quinapril is about 2.5 l/h and that of enalapril
about 18 l/h (Todd & Heel 1986, Halstenson et al. 1992). Both quinapril and quinaprilat
are highly bound to plasma proteins, about 97% (Olson et al. 1989). Enalaprilat is about
50% bound to plasma proteins (MacFadyen et al. 1993). The bioavailability of quinapril or
enalapril is not affected by food (MacFadyen et al. 1993, Plosker & Sorkin 1994). Plasma
concentrations of quinapril and enalapril are linear and dose-proportional at doses up to
80 mg once daily and 40 mg once daily (Todd & Heel 1986, Olson et al. 1989).
Renal and hepatic impairment affects the pharmacokinetics of quinapril and quinaprilat.
Quinapril and quinaprilat t½ increased by about 5-fold, Cmax by about 3-fold, and AUC by
about 10-fold in patients with renal impairment (Culy & Jarvis 2002). Markedly elevated
enalaprilat plasma concentrations were also seen in patients with severe renal impairment.
Quinaprilat Cmax and AUC are decreased by about 70% and 50% in patients with liver
cirrhosis (Culy & Jarvis 2002). A delay in the appearance of enalaprilat in plasma after a
single dose of enalapril was noted in patients with hepatic impairment (MacFadyen et al.
1993).
The pharmacokinetics of quinapril are not affected by concomitant administration of
hydrochlorothiazide, propranolol, or cimetidine, and quinapril does not affect the
pharmacokinetics of digoxin, hydrochlorothiazide, or warfarin (Culy & Jarvis 2002).
Quinapril can reduce the oral absorption of tetracycline, possibly due to binding of
tetracycline with magnesium in the quinapril tablet formulation (Culy & Jarvis 2002).
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There is no pharmacokinetic interaction between enalapril and furosemide,
hydrochlorothiazide, or digoxin (Todd & Heel 1986). In vitro, enalapril increases the
formation of the clopidogrel active cis 5-thiol metabolite due to inhibition of the CES1-
mediated hydrolysis of clopidogrel (Kristensen et al. 2014). In a pharmacoepidemiological
study with over 70000 patients with a myocardial infarction, concomitant use of ACE
inhibitors increased bleeding risk (Kristensen et al. 2014). This finding was, however, not
replicated in another study with over 45000 patients with a myocardial infarction
(Cressman et al. 2015).
Table 7. Pharmacokinetic properties of the study drugs’ carboxylic acid metabolites.
Oseltamivir
carboxylate
Clopidogrel
carboxylic acid
Quinaprilat Enalaprilat
Proportion of the parent
drug metabolized by
CES1 (%)
80 90 40 60
Distribution volume (l) 267 n/a n/a n/a
Protein binding (%) <3 94 97 50
tmax (h) 4 1 2 2-4
t½ (h) 7 8 25 36
Clearance (l/h) 25 10 13 8-10
Renal excretion (%) 60-70 50 30 40
Metabolite activity Active Inactive Active Active
Adapted from (Olson et al. 1989, MacFadyen et al. 1993, FDA 1997, Culy & Jarvis 2002, Widmer
et al. 2010).
CES1, carboxylesterase 1; n/a, not available; t½, elimination half-life; tmax, time to peak plasma
concentration.
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3 AIMS OF THE STUDY
The specific aims were as follows:
Study I To investigate the frequency distribution of the CES1
c.428G>A SNV in the Finnish population.
Studies I-III To investigate the effects of the CES1 c.428G>A SNV on the
pharmacokinetics of oseltamivir, clopidogrel, quinapril, and
enalapril and on the pharmacodynamics of clopidogrel,
quinapril, and enalapril in prospective genotype panel studies in
healthy volunteers.
Study IV To investigate the effects of sequence variations in close
proximity to or within the CES1 gene on its expression in whole
blood and the liver, and on the pharmacokinetics and
pharmacodynamics of clopidogrel.
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4 MATERIALS AND METHODS
4.1 Population genetic study
In total, 860 young (18-40 years) healthy white Finnish volunteers participated in the
population genetic study. The healthy volunteers were recruited from the University of
Helsinki student mailing lists during a time period of eight years. Following a written
informed consent, a 12-ml blood sample was drawn into an ethylenediaminetetraacetic acid
(EDTA) containing tube for genotyping and stored at -20°C until DNA extraction. The
health of the volunteers was ascertained by medical history before they entered the study.
DNA preparation and genotyping. Genomic DNA was extracted using standard methods
(QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany or Maxwell® 16 LEV Blood
DNA Kit on a Maxwell 16 Research automated nucleic acid extraction system, Promega,
Madison, WI, USA). DNA concentration and absorbance 260/280 ratio (A260/A280) were
determined with the NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA). The extracted DNA was stored at -20°C or -80°C until
genotyping. The subjects were genotyped for the CES1 c.428G>A SNV (rs71647871) by
allelic discrimination with a TaqMan® 5’-nuclease assay on an Applied Biosystems 7300
Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) or a QuantStudio™
12K Flex Real-Time PCR system (Life Technologies, Carlsbad, CA, USA) (forward
primer: 5´-TGATGGGAGTGTCCTCCCGAAG-3´ and reverse primer:
5´-GGGTAGGTAGTGTGTCCAATTAC-3´). The PCR volume was 8 μl in the 7300
Real-Time PCR system and 5 μl in the QuantStudio™ system. Pre- and post-PCR
fluorescence measurements and genotype calls were made with the 7300 Real-Time PCR
system or QuantStudioTM 12K Flex Real-Time PCR system. The PCR cycling conditions
were as follows: 1 cycle at 95°C for 10 minutes, followed by 40 cycles of melting at 95°C
for 15 seconds, and annealing and extending at 60°C for 1 minute. For the purpose of Study
II, the subjects were also genotyped for the CYP2C19*2 (c.681G>A, rs4244285), *3
(c.636G>A, rs4986893), and *17 (c.-806C>T, rs12248560) SNVs using the same reaction
volumes and PCR cycling conditions as above. About 10% of the samples were genotyped
in duplicate.
4.2 Pharmacokinetic and pharmacodynamic studies
4.2.1 Subjects
A total of 40 healthy Finnish volunteers participated in Studies I-III (14 females and 26
males) (Table 8). Four volunteers participated in all three studies. The subjects were
recruited from the pool of healthy genotyped subjects (see Materials and methods, section
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4.1) and selected based on the CES1 c.428G>A genotype. Before entering the studies, all
participants were given both oral and written information, and they gave written informed
consent.
In Study I, the subjects were allocated into one of three groups according to the
genotype: the CES1 c.428A/A group consisted of one participant, the c.428G/A group of
nine, and the c.428G/G (control) group of 12. The number of participants in Study I was
estimated to be sufficient to detect a 30% smaller oseltamivir carboxylate AUC0- between
different genotypes with a statistical power of 80% at an alpha level of 5%. In Studies II
and III, the subjects were allocated into one of two groups according the genotype: the
CES1 c.428G/A group consisted of 10 participants and the c.428G/G (control) group of 12.
In Study II, the subjects were balanced in two groups based on the CYP2C19*2, *3, and
*17 genotypes to minimize variability in clopidogrel pharmacokinetics due to these genetic
variants. In Studies II and III, the number of participants was estimated to be sufficient to
detect a 30% smaller metabolite to parent drug AUC0- ratio between different genotypes
(power 80%, alpha 5%).
The volunteers were ascertained to be healthy by medical history, physical examination,
and routine laboratory tests before entering the studies. Female subjects had a negative
pregnancy test before entering the studies. None of the participants used any continuous
medication, e.g., oral contraceptives, and no one was a tobacco smoker. Use of other drugs
was prohibited for one week before and three days after the study drug admistration. The
participants were instructed to abstain from consuming grapefruit products for three days
before and after study drug administration. Use of alcohol was prohibited the day before,
on the days of study drug administration, and on the following blood sampling days.
Participation in any other trial or blood donation within three months before and after each
study was also prohibited. Forceful physical exercise was prohibited on the day of
clopidogrel ingestion and on the following three days in Study II. Use of acetylsalicylic
acid, non-steroidal anti-inflammatory drugs, and omega-3-supplements was also prohibited
for one week before and after clopidogrel ingestion in Study II. Subjects with a systolic
blood pressure of more than 145 mmHg and less than 100 mmHg were not included in the
Study III. There were no withdrawals.
Study IV included whole blood DNA and RNA samples from 212 (whole blood discovery
cohort) and 106 (whole blood replication cohort) healthy volunteers, and whole blood DNA
and liver RNA samples from 201 patients (liver sample cohort). Good quality RNA and
gene expression data were obtained from 192 subjects in the whole blood discovery cohort,
88 in the whole blood replication cohort, and 177 in the liver sample cohort (Table 8). In
addition, Study IV included pharmacokinetic data on clopidogrel from all 106 healthy
volunteers in the whole blood replication cohort (49 women and 57 men; mean ± SD: age
24 ± 4 years, height 175 ± 9 cm, weight 71 ± 13 kg, and BMI 23 ± 3 kg/m2).
The whole blood discovery and replication cohort volunteers were ascertained to be
healthy by medical history, physical examination, and routine laboratory tests before
entering the studies. Female subjects had a negative pregnancy test before entering the
studies. None of the participants used any continuous medication, e.g., oral contraceptives,
and no one was a tobacco smoker. The liver samples were divided into the following three
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histological diagnosis categories: 1) normal liver without any steatosis, inflammation,
ballooning, or fibrosis, 2) simple steatosis without inflammation, ballooning, or fibrosis,
and 3) non-alcoholic steatohepatitis (NASH). The degree of steatosis was graded from 0 to
3 and that of lobular inflammation from 0 to 2. In the liver sample cohort, 70 patients had
type 2 diabetes, 29 had non-alcoholic fatty liver, 30 had NASH, and 54 used lipid-lowering
mediation. Before entering the studies, all participants were given both oral and written
information, and they gave a written informed consent. The studies were approved by the
Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa and the
Finnish Medical Agency Fimea (whole blood discovery and replication cohorts) and the
Ethics Committee of the Northern Savo Hospital District (liver sample cohort).
Table 8. Subject characteristics.
Study no Genotype Sex Age
(years)
Height
(cm)
Weight
(kg)
BMI
(kg/m2)
I CES1 c.428G/G
(n=12)
3 (f)
9 (m)
23 ± 4
23 ± 2
170 ± 9
183 ± 8
64 ± 3
81 ± 9
22 ± 1
24 ± 3
CES1 c.428G/A
(n=9)
4 (f)
5 (m)
26 ± 3
26 ± 4
164 ± 8
183 ± 9
53 ± 5
71 ± 7
20 ± 2
21 ± 2
CES1 c.428A/A
(n=1)
1 (m) 23 186 83 24
II and III CES1 c.428G/G
(n=12)
5 (f)
7 (m)
24 ± 6
24 ± 4
170 ± 6
180 ± 8
68 ± 15
80 ± 14
23 ± 4
25 ± 3
CES1 c.428G/A
(n=10)
4 (f)
6 (m)
28 ± 3
25 ± 5
166 ± 9
183 ± 7
56 ± 7
76 ± 8
20 ± 2
23 ± 2
IV Whole blood
(discovery)
n/a
(n=192)
99 (f)
93 (m)
24 ± 4
23 ± 3
167 ± 6
181 ± 6
62 ± 8
77 ± 11
22 ± 2
23 ± 3
IV Whole blood
(replication)
n/a
(n=88)
41 (f)
47 (m)
24 ± 4
24 ± 4
168 ± 7
182 ± 6
63 ± 9
78 ± 11
22 ± 3
24 ± 3
IV Liver n/a
(n=177)
122 (f)
55 (m)
48 ± 9
50 ± 8
n/a
n/a
n/a
n/a
44 ± 6
43 ± 5
Data are given as mean ± SD unless otherwise indicated.
BMI, body mass index; CES1, carboxylesterase 1; f, females; m, males; n/a, not available; SD,
standard deviation.
4.2.2 Study design
Studies I-III were prospective genotype panel studies, Study I with one study drug and
Studies II and III with a fixed order crossover design and three phases. Studies were carried
out at the Department of Clinical Pharmacology (University of Helsinki and Helsinki
University Hospital, Helsinki, Finland). Following an overnight fast, the subjects ingested
a single oral dose of oseltamivir, clopidogrel, quinapril, or enalapril with 150 ml of water
at 8 AM (Table 9). A standardized warm meal was served 4 hours and a standardized light
meal 7 and 10 hours after study drug ingestion. The subjects were under medical
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supervision for 12 hours after the study drug ingestion. In Studies II and III, a washout
period of at least one week was between the phases and food intake was identical in the
different study phases.
In Study IV, whole blood DNA and RNA samples from healthy volunteers were obtained
during eight pharmacokinetic studies (whole blood discovery and replication cohorts)
carried out at the Department of Clinical Pharmacology (Holmberg et al. 2014, Tornio et
al. 2014, Itkonen et al. 2015, Tarkiainen et al. 2015a, Itkonen et al. 2016, P.H. et al.
unpublished results, M.T.H. et al. unpublished results, M.K.I. et al. unpublished results).
Whole blood DNA and liver RNA samples were obtained from patients undergoing
laparoscopic gastric bypass operation, as part of the Kuopio Obesity Surgery Study (liver
sample cohort; Kuopio University Hospital, Kuopio, Finland; (Pihlajamäki et al. 2012,
Männisto et al. 2014, Nilsson et al. 2015). In addition, blood samples from 106 healthy
volunteers were obtained during seven pharmacokinetic studies on clopidogrel carried out
at the department of Clinical Pharmacology (whole blood replication cohort) (Holmberg et
al. 2014, Tornio et al. 2014, Itkonen et al. 2015, Tarkiainen et al. 2015b, Itkonen et al.
2016, M.T.H. et al. unpublished results, M.K.I. et al. unpublished results). In these
pharmacokinetic studies following an overnight fast, the subjects ingested a single oral dose
of 300 mg (n=49) or 600 mg (n=57) of clopidogrel with 150 ml of water at 8 or 9 AM
(Table 9). A standardized warm meal and light meals were served at prespecified time
points after clopidogrel ingestion. The subjects were under medical supervision for 12
hours after clopidogrel ingestion.
Table 9. Details of the drugs used in the studies.
Study Drug
substance
Dose (mg) Drug product Manufacturer
I Oseltamivir 75 Tamiflu tablet Roche Pharma AG, Grenzach-
Wyhlen, Germany
II Clopidogrel 600 Plavix tablet Sanofi Pharma Bristol-Myers
Squibb SNC, Paris, France
III Quinapril 10 Accupro tablet Pfizer, Freiburg, Germany
III Enalapril 10 Renitec tablet Merck Sharp & Dohme B.V.,
Haarlem, Netherlands
IV Clopidogrel 300 (n=49) or
600 (n=57)
Plavix tablet Sanofi Pharma Bristol-Myers
Squibb SNC, Paris, France
4.2.3 Sampling
In the prospective genotype panel studies (Studies I-III), a forearm vein of each participant
was cannulated for blood sampling on the days of study drug administration. Timed EDTA
blood samples (8 ml or 9 ml) were drawn prior to and for up to 12 hours after clopidogrel
ingestion, for up to 24 hours after quinapril ingestion, and for up to 48 hours after
oseltamivir and enalapril ingestion for the determination of study drug plasma
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concentrations. In Study II , part of the samples (4 ml) were derivatized immediately after
drawing with 25 μl of 500 mM 2-bromo-3’-methoxyacetophenone in acetonitrile to
stabilize the active cis 5-thiol metabolite, as previously described (Delavenne et al. 2010).
The sample tubes were then immediately placed on ice. Plasma was separated within 30
minutes by cold centrifugation (2100 g, 11 minutes). Urine was collected for up to 12 hours
after study drug ingestion. Plasma and urine aliquots were stored at -70°C or -80°C until
analysis.
In Study II, timed sodium citrate blood samples (2.7 ml each, containing 3.2% of sodium
citrate) were drawn prior to and for up to 12 hours after clopidogrel ingestion for
pharmacodynamic measurements. The tubes were inverted three to five times and stored in
room temperature for at least 10 minutes, as recommended by the manufacturer
(Accumetrics, San Diego, CA, USA). Whole blood platelet function tests were performed
within 4 hours.
In Study III, systolic and diastolic blood pressures and heart rates were measured twice
from the forearm with an automatic oscillometric blood pressure monitor (Omron M6W,
Omron Healthcare Co., Ltd., Kyoto, Japan), with the subjects in a sitting position, prior to
and at 4 and 12 hours after quinapril and enalapril ingestion.
In Study IV, fasting 2.5-ml whole blood RNA samples (PAXgene® Blood RNA tube;
PreAnalytiX GmbH, Hombrechtikon, Switzerland) and 9-ml whole blood DNA samples
were drawn prior to study drug ingestion during eight pharmacokinetic studies. The
PAXgene® Blood RNA sample tubes were stored at -70°C or -80°C until RNA extraction
and the whole blood DNA samples at -20°C or -80°C until DNA extraction. Fasting whole
blood DNA samples and liver biopsies were obtained from patients undergoing
laparoscopic gastric bypass operation. During the seven pharmacokinetic studies on
clopidogrel, a forearm vein of each participant was cannulated for blood sampling on the
days of study drug administration. Timed EDTA blood samples (4 ml or 9 ml) were drawn
prior to and for up to 4-24 hours after clopidogrel ingestion. The samples were handled as
in the Study II, including derivatization, plasma separation, and storing. Timed sodium
citrate samples (2.7 ml each, containing 3.2% of sodium citrate) were drawn prior to and
for up to 12-24 hours after clopidogrel ingestion in a subpopulation of 46 participants. The
samples were handled as in Study II.
4.2.4 RNA preparation and reverse transcription quantitative real-time PCR
In Study IV, RNA was extracted by standard methods using Maxwell® 16 LEV
simplyRNA Kit (Promega, Madison, WI, USA), including DNase I treatment, on the
Maxwell 16 Research system (whole blood discovery and replication cohorts) or miRNeasy
Mini Kit (liver sample cohort; Qiagen). Extracted RNA was stored at -80°C until
complementary DNA (cDNA) synthesis.
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The RNA was reverse transcribed using a High-Capacity cDNA Reverse Transcription
Kit (whole blood discovery cohort; Thermo Fisher Scientific) or a SuperScript® VILO
cDNA Synthesis Kit (whole blood replication and liver sample cohorts; Thermo Fisher
Scientific). Before quantitative real-time PCR (qPCR), the whole blood replication and
liver sample cohort cDNA samples were preamplified with a custom TaqMan pre amp pool
containing assays for the CES1 and reference genes (14 cycles; Thermo Fisher Scientific).
The qPCR was carried out using OpenArray technology on the QuantStudio™ 12K Flex
Real-Time PCR System. The custom OpenArray plate contained CES1 and reference gene
assays (Table 10), allowing the within-sample normalization with multiple reference genes.
Table 10. Assays used in quantitative real-time PCR.
Cohort Gene Assay ID
Whole blood (discovery)
CES1 Hs00275607_m1
DECR1 Hs00154728_m1
PPIB Hs00168719_m1
FPGS Hs00191956_m1
TRAP1 Hs00212474_m1
Whole blood (replication)
CES1 Hs00275607_m1
DECR1 Hs00154728_m1
PPIB Hs00168719_m1
FPGS Hs00191956_m1
B2M Hs00941230_m1
Liver
CES1 Hs00275607_m1
ACTB Hs01060665_g1
RPLP0 Hs99999902_m1
GAPDH Hs02758991_g1
B2M Hs00941230_m1
ACTB, actin beta; B2M, beta-2-microglobulin; CES1, carboxylesterase 1; DECR1, mitochondrial
2,4-dienoyl-coenzyme A reductase 1; FPGS, folylpolyglutamate synthase;   GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; PPIB, peptidylprolyl isomerase B; RPLP0,  ribosomal
protein lateral stalk subunit P0; TRAP1, tumor necrosis factor receptor associated protein 1.
4.2.5 DNA preparation, sequencing and genotyping
In Study IV, genomic DNA was extracted using the Maxwell 16 LEV blood DNA Kit on
the Maxwell Research system (whole blood discovery and replication cohorts) or DNeasy
Blood & Tissue Kit (liver sample cohort; Qiagen).
Targeted resequencing of the CES1 gene ± 20 kb (chr16: 55,816,763-55,887,075;
genome build GRCh37) was performed in all whole blood discovery cohort participants
(n=212). For library preparation, genomic DNA was processed according to the NEBNext
DNA Sample Prep protocol (New England BioLabs, Ipswich, MA, USA). Target
enrichment capture was performed using the NimbleGen SeqCap EZ Choice capture
57
protocol (Roche sequencing, Pleasanton, CA). Sequencing was done on the Illumina
HiSeq2000 platform with 100 bp paired-end reads (Illumina, San Diego, CA, USA).
Quality control, short read alignment, and variant calling and annotation were carried out
using a pipeline developed at the Technology Center at the Institute for Molecular Medicine
Finland (FIMM; Helsinki, Finland). The sequencing and bioinformatics pipelines were
carried out at the FIMM.
The whole blood and liver samples were genotyped for the CES1 c.52+579A>G
(rs12443580) and c.257+885T>C (rs8192935) SNVs with custom TaqMan® 5´-nuclease
assays using OpenArray technology on the QuantStudio™ 12K Flex Real-Time PCR
System. Call identity with sequencing data was 99.4% and 100% for the rs12443580 and
rs8192935 SNVs. The replication cohort samples were also genotyped for the CES1
c.428G>A (p.G143E, rs71647871) and CYP2C19*2 (c.681G>A, rs4244285), *3
(c.636G>A, rs4986893), and *17 (c.-806C>T, rs12248560) SNVs with TaqMan
5´-nuclease assays using OpenArray technology on the QuantStudio™ 12K Flex Real-
Time PCR System.
4.3 Determination of drug concentrations
Oseltamivir. Prior to analysis, a simple protein precipitation of plasma samples by
acetonitrile was performed, except for the very low oseltamivir plasma concentrations (24,
34, and 48-h samples) that were prepared by a MCX solid phase extraction (Waters,
Milford, MA, USA). The plasma oseltamivir and oseltamivir carboxylate concentrations
were measured using an API 3000 liquid chromatography-tandem mass spectrometry
system (AB Sciex, Toronto, Canada) (Table 11). Deuterated oseltamivir and deuterated
oseltamivir carboxylate served as internal standards.
Clopidogrel. The plasma concentrations of clopidogrel, clopidogrel active cis 5-thiol
metabolite, clopidogrel carboxylic acid, and clopidogrel acyl-ȕ-D-glucuronide were
measured with a Nexera X2 liquid chromatography instrument (Shimadzu, Kyoto, Japan)
coupled to a QTRAP 5500 tandem mass spectrometer (AB Sciex, Toronto, ON, Canada)
(Table 11), according to a previously described method with slight modifications (Tornio
et al. 2014, Holmberg et al. 2014). Plasma sample preparation was automated using a 96-
well Phree phospholipid removal plate (Phenomenex, Torrance, CA, USA) conducted on a
Freedom EVO automated liquid handling system (Tecan Group, Männedorf, Switzerland).
Deuterium labeled forms of clopidogrel, the active metabolite methylphenacyl derivative,
and clopidogrel carboxylic acid served as internal standards. No other clopidogrel
metabolite interfered with the assay.
Quinapril and enalapril. Plasma samples were prepared for analysis by protein
precipitation in acetonitrile containing the internal standards, deuterated quinapril,
deuterated enalapril, and deuterated enalaprilat. Deuterated quinapril served as an internal
standard for both quinapril and quinaprilat. Urine samples were diluted with the acetonitrile
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internal standard solution and centrifuged prior to analysis. The drug concentrations were
determined by using an Agilent 1100 series liquid chromatography system (Agilent
Technologies, Waldbronn, Germany) coupled to an API 2000 tandem mass spectrometer
(AB Sciex, Toronto, Ontario, Canada) (Table 11). In urine, the lower limit of quantification
was 10 ng/ml for all analytes and the intra-day coefficients of variation were below 3.5%
at relevant concentrations for all analytes (n=6).
Table 11. Summary of the plasma quantification methods.
Study Analyte LC-MS-MS system Lower limit of
quantification
(ng/ml)
Interday CV
I Oseltamivir AB Sciex API 3000 0.04 <10% (n=5)
Oseltamivir
carboxylate
AB Sciex API 3000 1.0 <10% (n=5)
II Clopidogrel Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
0.05 <6% (n=4)
Active cis 5-thiol
metabolite
Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
0.05 <10% (n=4)
Clopidogrel
carboxylic acid
Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
100 <7% (n=4)
Clopidogrel acyl-β-
D-glucuronide
Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
100 <10% (n=4)
III Quinapril Agilent 1100 - AB Sciex API
2000
0.5 <3% (n=8)
Quinaprilat Agilent 1100 - AB Sciex API
2000
1.0 <5% (n=8)
III Enalapril Agilent 1100 - AB Sciex API
2000
0.5 <4% (n=7)
Enalaprilat Agilent 1100 - AB Sciex API
2000
1.0 <7% (n=7)
IV Clopidogrel Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
0.01-0.1 <15% (n=21)
Active cis 5-thiol
metabolite
Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
0.01-0.1 <15% (n=21)
Clopidogrel
carboxylic acid
Shimadzu Nexera X2 - AB
Sciex 5500 Qtrap
20-100 <15% (n=19)
CV, coefficient of variation; LC-MS-MS, liquid chromatography-tandem mass spectrometry.
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4.4 Pharmacokinetic analysis
In Study I, the pharmacokinetic variables of oseltamivir and oseltamivir carboxylate were
calculated by conventional non-compartmental methods using MK-Model, version 5.0
(Biosoft, Cambridge, UK). The terminal log-linear part of each concentration-time curve
was identified visually, and the elimination rate constant (ke) was determined from
logarithmically transformed data with linear regression analysis. The t½ was calculated with
the equation t½ = ln2/ke. The AUC0- was calculated by a combination of the linear and
log-linear trapezoidal rules (linear up and logarithmic down), with extrapolation to infinity
by division of the last measured concentration by ke.
In Studies II-IV, the Cmax, tmax, t½, and AUC0- values were calculated for clopidogrel, the
active cis 5-thiol metabolite, clopidogrel carboxylic acid, clopidogrel acyl-ȕ-D-
glucuronide, quinapril, quinaprilat, enalapril, and enalaprilat with standard non-
compartmental methods using log-linear trapezoidal rules with Phoenix WinNonlin,
version 6.3 (Certara, St. Louis, MO, USA). The amount excreted into urine from 0 to 12 h
(Ae) and renal clearance (Clrenal) of quinapril and enalapril were calculated using Phoenix
WinNonlin, version 6.3. All the AUC0-,  Cmax, and Ae values were adjusted for a 70 kg
body weight.
4.5 Pharmacodynamic analysis
Platelet function testing. In Studies II and IV, antiplatelet activity was tested with a
turbidimetric optical detection system (VerifyNow P2Y12 Test, Accumetrics, San Diego,
CA) in the sodium citrate anticoagulated whole blood samples. In the test device,
ADP-activated platelets aggregate on fibrinogen-coated microparticles in one channel. The
resultant change in light transmittance is measured and expressed as P2Y12 reaction units
(PRU). In a second channel of the test device, platelets are activated with a thrombin
receptor-activating peptide and protease-activated receptor 4 activating peptide, and the
baseline platelet function is measured. The percentage of drug-induced inhibition of
P2Y12-mediated platelet aggregation is measured by comparing the aggregation in the two
channels (Malinin et al. 2007, Lordkipanidze et al. 2008, Jeong et al. 2012).
Blood pressure and heart rates. In Study III, the pharmacodynamics of quinapril and
enalapril were characterized by average systolic and diastolic blood pressures and average
heart rates (the mean value of the two measurements was used), calculated by dividing the
area under the effect-time curve from 0 to 12 h by 12 h.
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4.6 Statistical analysis
Population genetic study (Study I). The SNV frequency is given with 95% confidence
intervals (CIs). Deviation from Hardy-Weinberg equilibrium was tested using the Fisher’s
exact test.  We considered P values below 0.05 statistically significant.
Pharmacokinetic and pharmacodynamic studies (Studies I-IV). In Studies I-III, the
data were analyzed using the statistical program IBM SPSS 19.0 for Windows (Chicago,
IL, USA). The AUC0-, Cmax, and Ae values were adjusted for a 70-kg body weight. Except
for tmax, the pharmacokinetic variables were logarithmically transformed before analysis.
Differences in the pharmacokinetic (except tmax) and pharmacodynamic variables between
the genotypes were investigated using analysis of variance (ANOVA). The tmax values were
compared using the Mann-Whitney U test. Differences were considered statistically
significant when P was below 0.05.
In Study IV, the data were analyzed using the statistical programs JMP Genomics 7.0
(SAS Institute Inc., Cary, NC) and IBM SPSS 22.0 for Windows (Armonk, NY). Possible
effects of demographic covariates on CES1 whole blood and liver expression were
investigated using a forward stepwise linear regression analysis. For the whole blood
discovery cohort, age, sex, and body weight were used as demographic variables and for
the liver sample cohort, age, sex, BMI, type 2 diabetes, degree of lobular inflammation and
steatosis, and use of lipid-lowering medication were used. The P value thresholds of 0.05
and 0.10 were employed for entry into and removal from the model. The effects of CES1
genetic variants on its whole blood expression in the discovery cohort were then
investigated using a forward stepwise linear regression analysis adjusting for demographic
covariates as necessary. P values were adjusted with the Benjamini-Hochberg false
discovery rate (FDR) method. A P value threshold of 0.05 was employed for entry of
genetic variants into the model. For the whole blood replication and liver sample cohorts,
the analysis was carried out using linear regression analysis adjusting for demographic
covariates as necessary. The AUC0- and Cmax values were adjusted for a 70-kg body
weight. Except for the tmax, the pharmacokinetic variables were logarithmically transformed
before analysis. Differences in the pharmacokinetic (except tmax) and pharmacodynamic
variables were investigated using a forward stepwise linear regression analysis, with
demographic covariates, CES1 and CYP2C19 genotypes, and clopidogrel dose as
independent variables. The tmax values were compared using Kruskal-Wallis 1-way
ANOVA. Differences were considered statistically significant when the P was below 0.05.
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5 RESULTS
5.1 Population genetic study (Study I)
Among 860 healthy white Finnish volunteers, the CES1 c.428G>A variant allele was found
with a frequency of 2.2% (95% CI, 1.6-3.0%). This is slightly less than seen in a previous
study of 455 white subjects (3.7%) and similar to that in 299 Hispanics (2.0%) (Zhu et al.
2008). Only 1 of the 860 subjects showed a homozygous variant genotype (0.05%, 95% CI,
0.02-0.7%), while 4.3% (95% CI, 3.0-5.7%) were heterozygous carriers. We found no
deviation from the Hardy-Weinberg equilibrium (P>0.999).
5.2 Effects of the CES1 c.428G>A variant on drug
pharmacokinetics (Studies I-III)
Oseltamivir. The AUC0- of oseltamivir and oseltamivir carboxylate varied 6.8-fold and
1.8-fold between individual subjects (n=22). The mean AUC0- of oseltamivir was 18%
larger in subjects with the CES1 c.428G/A genotype (n=9) than those with the c.428G/G
genotype (n=12) (P=0.025) (Figure 8). Subjects with the c.428G/A genotype also had a
15% lower Cmax of oseltamivir carboxylate than subjects with the c.428G/G genotype
(P=0.011). The oseltamivir carboxylate to oseltamivir AUC0- ratio was 23% smaller in
subjects with the CES1 c.428G/A genotype than in those with the c.428G/G genotype
(P=0.006). The CES1-catalyzed bioactivation of oseltamivir to oseltamivir carboxylate was
reduced to a much greater extent in the one CES1 c.428A/A homozygote than in the
c.428G/A heterozygotes (Figure 8). The AUC0- of oseltamivir was 360% or 290% larger
in the one subject with the CES1 c.428A/A genotype than in those with the c.428G/A or
c.428G/G genotype. Consistently, the AUC0- of oseltamivir carboxylate was 20% or 27%
smaller in the one subject with the CES1 c.428A/A genotype than in those with the
c.428G/A or c.428G/G genotype. Furthermore, in the one subject with the CES1 c.428A/A
genotype, the oseltamivir carboxylate to oseltamivir AUC0- ratio was 79% or 84% smaller
than in those with the c.428G/A or c.428G/G genotype. The t½ and tmax of oseltamivir and
oseltamivir carboxylate were not affected by the CES1 c.428G>A SNV.
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Figure 8. Effect of the CES1 c.428G>A SNV on the pharmacokinetic variables of
oseltamivir. Bars represent geometric mean ratios and whiskers 90% CIs.
AUC0-∞, area under the concentration-time curve from 0 hours to infinity;
CES1, carboxylesterase 1; CI, confidence interval; Cmax, peak plasma
concentration; t½, elimination half-life.
Clopidogrel. The AUC0- of the parent clopidogrel varied 13-fold between individual
subjects (n=22). The geometric mean AUC0- and Cmax of clopidogrel were 123% and
109% higher in subjects with the CES1 c.428G/A genotype than in those with the c.428G/G
genotype (P=0.004 and P=0.035)  (Figure 9). The AUC0- of the active metabolite varied
6.3-fold between individual subjects (n=22). The AUC0- and Cmax of clopidogrel active
cis 5-thiol metabolite were 67% and 63% higher in subjects with the CES1 c.428G/A
genotype than in those with the c.428G/G genotype (P=0.009 and P=0.017). The CES1
c.428G>A SNV had no significant effect on the plasma concentrations of carboxylic acid
or glucuronide metabolites. The clopidogrel carboxylic acid to clopidogrel and clopidogrel
acyl-ȕ-D-glucuronide to clopidogrel AUC0- ratios were 53% and 58% smaller in subjects
with the CES1 c.428G/A genotype than in those with the c.428G/G genotype (P=0.009 and
P=0.007). In contrast, the active metabolite to clopidogrel and clopidogrel
acyl-ȕ-D-glucuronide to clopidogrel carboxylic acid      AUC0- ratios were not significantly
affected by the CES1 c.428G>A SNV. The t½ and  tmax of clopidogrel or any of its
metabolites were not affected by the CES1 c.428G>A SNV. Exclusion of the
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loss-of-function CYP2C19*2 allele and gain-of-function CYP2C19*17 allele carriers from
the analysis did not change the results regarding the effects of the CES1 c.428G>A SNV.
Figure 9. Effect of the CES1 c.428G>A SNV on the pharmacokinetic variables of
clopidogrel. Bars represent geometric mean ratios and whiskers 90% CIs.
AUC0-∞, area under the concentration-time curve from 0 hours to infinity;
CES1, carboxylesterase 1; CI, confidence interval; Cmax, peak plasma
concentration; t½, elimination half-life.
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In line with the pharmacokinetic effects, the CES1 genotype significantly affected the
platelet inhibitory effect of clopidogrel (Figure 10). The average platelet aggregation
activity at 0-12 hours after clopidogrel dosing was 61 P2Y12 reaction units (PRUs) lower
in subjects with the CES1 c.428G/A genotype than those with the c.428G/G genotype
(P=0.015). In subjects with the CES1 c.428G/A genotype, the average percentage inhibition
of P2Y12-mediated platelet aggregation at 0-12 hours was 19 percentage points higher than
in those with the c.428G/G genotype (P=0.036). The maximum observed platelet inhibition
was 19 percentage points higher and the minimum observed platelet aggregation activity
was 59 PRUs lower in subjects with the CES1 c.428G/A genotype than in those with the
c.428G/G genotype (P=0.041 and P=0.026). Exclusion of the CYP2C19*2 allele carriers
from the analysis did not change the results.
Figure 10. Effect of the CES1 c.428G>A SNV on the antiplatelet functions of
clopidogrel. Bars represent geometric mean ratios and whiskers 90%
CIs.CES1, carboxylesterase 1; CI, confidence interval; PRU, P2Y12 reaction
unit.
Quinapril and enalapril. The AUC0- of quinapril and that of quinaprilat varied 3.5-fold
among all subjects (n=22). The CES1 c.428G>A genotype had no significant effect on the
pharmacokinetic or pharmacodynamic variables of quinapril (Figure 11).
The AUC0- of enalapril and that of enalaprilat varied 2.8-fold and 2.7-fold among all
subjects (n=22). The AUC0- of enalaprilat was 20% lower in subjects with the CES1
c.428G/A genotype than in those with the c.428G/G genotype (P=0.049) (Figure 11).
Accordingly, enalaprilat Ae was 35% smaller in subjects with the CES1 c.428G/A genotype
than those with the c.428G/G genotype (P=0.044). Otherwise, the CES1 genotype had no
significant effect on any other pharmacokinetic or pharmacodynamic variable of enalapril.
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Figure 11. Effect of the CES1 c.428G>A SNV on the pharmacokinetic variables of
quinapril and enalapril. Bars represent geometric mean ratios and whiskers
90% CIs. AUC0-∞, area under the concentration-time curve from 0 hours to
infinity; CES1, carboxylesterase 1; CI, confidence interval; Cmax, peak
plasma concentration; t½, elimination half-life.
5.3 Effects of CES1 genetic variants on its expression, and
clopidogrel pharmacokinetics and pharmacodynamics (Study IV)
Massively parallel sequencing. A total of 279 sequence variants with MAFs of at least 1%
were discovered within 20 kb upstream and downstream of the CES1 gene among the 192
participants. Seven of the variants were located in the coding sequence, 100 in the upstream
region, 128 in the introns, and 44 downstream.
CES1 expression. CES1 gene expression in whole blood was on average 11% relative to
the mean expression of the endogenous control genes and varied 81-fold among the study
participants (n=192). Of the 279 sequence variants, a total of 140 variants were associated
with CES1 expression with FDR-corrected P values below 0.05. In a forward stepwise
linear regression analysis, demographic covariates (age, sex, and body weight) were not
associated with CES1 expression. Two SNVs, however, showed independent associations
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with CES1 expression (Figure 12). The SNV with the strongest observed effect, rs12443580
(c.52+579T>C, MAF of 35%) located in intron 1, was associated with a 39% reduction in
CES1 expression by each copy of the minor allele (P=4.0 x 10-13). The rs8192935
(c.257+885G>A; MAF of 31%) SNV, located in intron 2, was associated with an additional
31% reduction in CES1 expression per copy of the minor allele (P=2.5 x 10-8).  In  a
replication cohort of 88 whole blood samples, rs12443580 was associated with a 28%
reduction and rs8192935 a 25% reduction of CES1 expression per copy of the minor allele
(P=0.0015 and 0.0091).
CES1 expression in the liver was on average 209% relative to the mean expression of
endogenous control genes, and varied 9-fold between the samples (n=177). In a forward
stepwise linear regression analysis, demographic covariates (age, sex, BMI, type 2 diabetes,
degree of lobular inflammation or steatosis, and the use of lipid-lowering drugs) were not
associated with CES1 expression. Moreover, the CES1 rs12443580 and rs8192935 SNVs
showed no significant association with CES1 expression in the liver samples.
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Figure 12. Scatter plots of the effects of rs12443580 and rs8192935 SNVs on CES1
expression in whole blood and the liver. The lowest expression level within
the discovery samples (A), replication samples (B), and liver samples (C) was
set as 1. The horizontal lines represent the median. Individual data points
are given as circles for men and as triangles for women. CES1,
carboxylesterase 1; SNV, single nucleotide variation.
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Pharmacokinetics and pharmacodynamics of clopidogrel. In a forward stepwise linear
regression analysis, the clopidogrel carboxylic acid to clopidogrel AUC0- ratio was 58%
lower per copy of the CES1 c.428G>A variant allele (90% CI, 38-72%; P=0.0004), 74%
higher following a 600 mg dose (n=57) than 300 mg dose (n=49) of clopidogrel (90% CI,
35-124%; P=0.0005), and 1.9% lower per 1 kg body weight (90% CI, 0.9-2.8%; P=0.001)
(Figure 13). The AUC0- of clopidogrel was 163% (90% CI, 76-293%; P=0.0001) and that
of the active cis 5-thiol metabolite 60% (90% CI, 22-110%; P=0.005) higher per copy of
the CES1 c.428G>A variant allele. The CES1 rs12443580 and rs8192935 or CYP2C19
SNVs were not significantly associated with any pharmacokinetic variable, but the AUC0-
 of the active cis 5-thiol metabolite was 13% lower per copy of the CYP2C19 c.681G>A
variant allele (*2, rs4244285; P=0.058).
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Figure 13. Scatter plots of the effects of CES1 c.428G>A SNV (rs71647871) on
dose-adjusted clopidogrel carboxylic acid to clopidogrel AUC0-∞ ratio (A),
dose- and weight-adjusted clopidogrel AUC0-∞ (B), and dose- and
weight-adjusted active metabolite AUC0-∞ (C). The horizontal lines represent
the median. Individual data points are given as circles for men and as
triangles for women. AUC0-∞, the area under the plasma concentration-time
curve from 0 hours to infinity; CES1, carboxylesterase 1; SNV, single
nucleotide variation.
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The average and minimum platelet aggregation activities at 0-12 hours after clopidogrel
dosing were 68 PRUs and 64 PRUs lower per copy of the CES1 c.428G>A variant allele
(90% CIs, 39-97 PRUs and 35-93 PRUs, P=0.0003 and P=0.0006). Both the average and
maximum percentage inhibition of P2Y12-mediated platelet aggregation at 0-12 hours after
clopidogrel dosing were 21 percentage points higher per copy of the CES1 c.428G>A
variant allele (90% CIs, 11-31% and 11-32%; P=0.009 and P=0.001; Figure 14). In
comparison, the average and maximum percentage inhibition of P2Y12-mediated platelet
aggregation at 0-12 hours were 12 and 13 percentage points  lower per copy of the
CYP2C19 c.681G>A variant allele (90% CIs, 5-20% and 5-21%; P=0.01 and P=0.01). The
CES1 rs12443580 and rs8192935 SNVs had no significant effect on the pharmacodynamics
of clopidogrel.
Figure 14. Scatter plots of the effects of CES1 c.428G>A (rs71647871) and CYP2C19
c.681G>A (*2, rs4244285) SNVs on the average platelet inhibition of a
600 mg oral dose of clopidogrel. The horizontal lines represent the median.
Individual data points are given as circles for men and as triangles for
women. CES1, carboxylesterase 1; CYP, cytochrome P450; SNV, single
nucleotide variation.
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6 DISCUSSION
6.1 Methodological considerations
Population genetic study (Study I). In the population genetic study, 860 DNA samples
were genotyped from healthy white Finnish volunteers. The investigated SNV was selected
based on a previous in vivo study, in which the CES1 c.428G>A SNV markedly reduced
the hydrolysis of methylphenidate (Zhu et al. 2008). The large number of participants
reduced random sampling error affecting the results of allele frequency. The investigated
allele frequency was in Hardy-Weinberg equilibrium. The genotype data was analyzed in
a coded form. The information on the genotypes and the volunteers was kept in secured
files with limited access. There were no reported adverse effects and no study withdrawals
Pharmacokinetic and pharmacodynamic studies. The prospective genotype panel
studies (Studies I-III) were carried out with 40 healthy volunteers with different CES1
c.428G>A SNV genotypes. The CES1 c.428G>A SNV and especially the homozygous A/A
genotype are rare in Caucasians; about 0.04-0.2% are homozygous for the CES1 c.428G>A
variant allele. Therefore, the number of possible heterozygous and homozygous individuals
to be considered for participation in the Studies I-III was small. Study I included only one
homozygous individual and 9 heterozygous individuals, and Studies II and III had no
homozygous individuals and only 10 heterozygous. In Study II, the subjects were also
genotyped for the CYP2C19*2, *3, and *17 alleles, because it was not possible to target
subjects who had the CES1 c.428G/A SNV and were without altered function CYP2C19
alleles. The two CES1 genotype groups, however, were balanced with respect to the
reduced function CYP2C19 alleles. In these prospective genotype panel studies, the
subjects were not genotyped for any other variants, and therefore it is not possible to
exclude the affect other CES1 variants or variants in some other genes might have on the
pharmacokinetics and pharmacodynamics of the study drugs. Study IV included samples
obtained from seven pharmacokinetic studies on clopidogrel carried out at the Department
of Clinical Pharmacology (22 samples from Study II and 84 samples from the other
studies). Therefore, in Study IV, the CES1 c.428G>A variant allele was overrepresented,
as the study included participants from a genotype panel study focusing on this variant
(Study II). This overrepresentation could have overshadowed the effects of CYP2C19
variants.
In the prospective genotype panel studies (Studies I-III), no significant differences in
age, height, weight, or BMI were observed between the groups. In Study IV, the
demographic variables (age, sex, and BMI) were different between the two whole blood
and liver sample cohorts. The CES1 whole blood or liver expression was, however, not
associated with these variables. This diverges from previous studies with smaller sample
sizes, which suggested possible effects of age and sex on CES1 liver expression (Hosokawa
et al. 1995, Zhu et al. 2009a, Xu et al. 2016). Age, sex, and BMI were associated with
CES1 expression in adipose tissue in elderly twins (Friedrichsen et al. 2013). When
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appropriate, the pharmacokinetic variables were adjusted for body weight. To further
reduce variation, restrictions were imposed on the use of other drugs, alcohol, grapefruit
juice, and supplements before and during the pharmacokinetic studies. In addition, the
study drugs were administered after an overnight fast and food intake during the study days
was standardized and controlled. In Study IV, 11 individuals with a non-Caucasian
background or excess relatedness (siblings) were excluded from the analysis.
In clinical practice, oseltamivir is usually administered for a course of 5 days, and
clopidogrel, quinapril, and enalapril on a regular basis. The steady-state plasma
concentrations of oseltamivir, clopidogrel, quinapril, and enalapril have been predictable
from their pharmacokinetic variables obtained after single doses. The relative differences
in the steady-state AUCs between individuals with different CES1 c.428G>A SNV
genotypes should be similar to the AUC differences observed after a single dose. Therefore,
in the prospective genotype panel studies, a single dose was chosen for safety and practical
reasons. The doses of study drugs corresponded to their normal therapeutic doses. In Study
IV, the clopidogrel dose varied from 300 mg to 600 mg between the seven different
pharmacokinetic studies. The clopidogrel dose was therefore treated as an independent
variable in the linear regression analysis. Six healthy volunteers participated in more than
one of the pharmacokinetic studies on clopidogrel (Study IV), and only samples from one
of these studies were included in the pharmacokinetic and statistical analyses.
In the genotype panel studies, the sampling schedule was selected to cover the plasma
concentration-time curve sufficiently in order to provide a reliable estimate of the extent of
exposure. Timed EDTA blood samples were drawn for up to 12-48 hours after study drug
ingestion, due to varying elimination kinetics of the drugs. Based on the study drugs’
elimination half-lives, a washout period of at least one week in Studies II and III was
sufficient to minimize possible carry-over effects . Urine was collected only during the time
spent at the Clinical Research Unit to ensure compliance.
In Study IV, the sampling schedule varied from 4 hours to 24 hours between the seven
different pharmacokinetic studies. Only timed EDTA blood samples drawn for up to 4
hours and 12 hours were used in the pharmacokinetic analysis. The sodium citrate
anticoagulated whole blood samples were obtained from only 46 participants and these
blood samples were drawn for up to 12-24 hours after clopidogrel ingestion. All of these
participants, however, had ingested a 600 mg dose of clopidogrel and only samples drawn
for up to 12 hours were used in the pharmacodynamic analysis.
In the pharmacokinetic studies, there were no reported adverse effect and no study
withdrawals. The liver biopsies were obtained during laparoscopic gastric bypass surgery
minimizing procedure-related complications (such as risk of bleeding and injury to a nearby
tissue) in comparison to percutaneously obtained liver biopsies.
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6.2 Population genetics (Study I)
Interethnic differences are common in the frequencies of genetic variants affecting drug
pharmacokinetics (Li et al. 2011). The CES1 c.428G>A variant allele was less common in
the Finnish population (2.2%) than in European-Americans (4%) (Zhu et al. 2008). This
difference may be explained by a founder effect of the Finnish population or population
admixture in the European-American population.
6.3 Effects of the CES1 c.428G>A SNV on drug pharmacokinetics
and pharmacodynamics (Studies I-III)
Oseltamivir. This was the first study showing that the CES1 c.428G>A SNV affects the
pharmacokinetics of oseltamivir, indicative of the important role that CES1 plays in the
bioactivation of oseltamivir in vivo. Subjects with the CES1 c.428G/A genotype had a
significantly smaller oseltamivir carboxylate to oseltamivir AUC0- ratio, a larger AUC0-
of oseltamivir, and lower Cmax of oseltamivir carboxylate than subjects with the c.428G/G
genotype. Notably, in the one subject with the CES1 c.428A/A genotype, the hydrolysis of
oseltamivir to oseltamivir carboxylate was even more impaired. In that subject, the
oseltamivir carboxylate to oseltamivir AUC0- ratio was about 80% to 85% smaller, the
AUC0- of oseltamivir about 300% to 400% larger, and the AUC0- of oseltamivir
carboxylate 20% to 25% smaller than in the subjects with the c.428G/A or c.428G/G
genotype.
The results are in good agreement with a previous in vitro study, in which the c.428G>A
variant allele markedly decreased the enzymatic activity of CES1, and with a recent in vitro
study, in which the c.428G>A variant reduced the bioactivation of oseltamivir by about
60% (Zhu & Markowitz 2013, Shi et al. 2016a).
Clopidogrel. The CES1 c.428G>A SNV affected the pharmacokinetics and
pharmacodynamics of clopidogrel, demonstrating that CES1 plays an important role in the
formation of the inactive clopidogrel carboxylic acid metabolite in vivo. Clopidogrel
carboxylic acid to clopidogrel AUC0- ratio was about 50% less in subjects with the CES1
c.428G/A genotype than in subjects with the c.428G/G genotype, indicating reduced
hydrolysis of parent clopidogrel. Consequently, the AUC0- of clopidogrel was about 120%
larger and the AUC0- of active metabolite was about 70% larger in subjects with the CES1
c.428G/A genotype than in subjects with the c.428G/G genotype. The AUCs of the
clopidogrel carboxylic acid and acyl-ȕ-D-glucuronide metabolites remained unchanged. Of
note, the plasma exposures to the carboxylic acid and glucuronide metabolites are more
than 1000-fold compared to the exposures to the parent clopidogrel and its active
metabolite. Therefore, even a small shift from the hydrolytic pathway towards the oxidative
activating pathway should result in a significant increase in exposures to the parent
clopidogrel and the active metabolite, but only a small increase with carboxylic acid and
glucuronide metabolites exposure.
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Consistent with the pharmacokinetic findings, the CES1 c.428G>A variant allele
markedly enhanced the platelet inhibitory effect of clopidogrel. The average platelet
aggregation activity was 61 PRUs lower and the minimum platelet aggregation activity 59
PRUs lower in subjects with the CES1 c.428G/A genotype than those with the c.428G/G
genotype. In addition, both the average and maximum observed percentage platelet
aggregation inhibitions were 19 percentage points higher in subjects with the CES1
c.428G/A genotype.
In comparison, healthy volunteers carrying one or two well-established loss-of-function
CYP2C19 c.681G>A (*2, rs4244285) or c.636G>A (*3, rs4986893) alleles have been
shown to have about 30-45% lower systemic exposure to the active metabolite and about
10-20 percentage point reduction in the antiplatelet effect of clopidogrel in ex vivo light
transmission aggregometry (Brandt et al. 2007, Mega et al. 2009). Study II did not include
any CYP2C19 c.636G>A variant allele carriers and this exclusion did not change the
results. Furthermore, CYP2C19 c.681G>A allele carriers tended to have only a slightly
reduced exposure to the active metabolite.  The overrepresentation of the CES1 variant
allele carriers, however, may have overshadowed the effects of the CYP2C19 c.681G>A
SNV.
The results are in good agreement with previous in vitro studies and a recent
physiology-directed population pharmacokinetic/pharmacodynamic model indicating a
major role for CES1 in the biotransformation of clopidogrel (Tang et al. 2006, Zhu et al.
2013, Jiang et al. 2016). They also provide a mechanistic explanation for the previously
observed association between the CES1 c.428G>A SNV and clopidogrel active metabolite
plasma concentrations (Lewis et al. 2013). In addition, the effect of the c.428G>A SNV on
clopidogrel pharmacokinetics and pharmacodynamics seems to be similar in size to that of
well-established loss-of-function CYP2C19 alleles (Kim et al. 2008, Mega et al. 2009,
Shuldiner et al. 2009, Scott et al. 2013), but with an opposite direction.
Clopidogrel could serve as a probe substrate for CES1 in drug interaction and
pharmacogenetic studies in humans despite its weaknesses (e.g., metabolized by several
CYPs) since its hydrolysis is highly sensitive to altered CES1 activity.
Quinapril and enalapril. The CES1 c.428G>A SNV had no observable effect on the
pharmacokinetics or pharmacodynamics of quinapril. The AUC0- of active enalaprilat was
20% smaller in subjects with the CES1 c.428G/A genotype than in subjects with the
c.428G/G genotype. Consequently, the Ae of enalaprilat was 35% smaller in subjects with
the CES1 c.428G/A genotype than those with the c.428G/G genotype. Otherwise, the CES1
polymorphism had no significant effect on the pharmacokinetics or pharmacodynamics of
enalapril.
The lack of effect on quinapril biotransformation and the smaller than expected effect
on enalapril biotransformation can be partially explained by overlapping substrate
specificities of carboxylesterases. Quinapril is also hydrolyzed by CES2 (Takai et al. 1997),
and therefore, the significance of CES1 in the bioactivation of quinapril is likely to be
smaller than in that of enalapril. The higher fraction of oral enalapril (60%) bioactivated
compared to that of quinapril (40%) can also contribute to the different effect size of the
c.428G>A SNV on their pharmacokinetics.
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These results are in good agreement with previous in vitro and in vivo studies on the
effects of CES1 c.428G>A variant allele on the pharmacokinetics of other widely used
CES1 substrate drugs (Patrick et al. 2007, Wang et al. 2016). In these studies, the effect
size has been of the same magnitude or larger than seen on enalapril.
Since the CES1 c.428G>A SNV had no observable effect on the pharmacokinetics of
quinapril and only a modest effect on the pharmacokinetics of enalapril, they are likely not
sensitive probe drugs for CES1 activity in humans. This suggests that ACE inhibitors differ
in their liability to the effects of the CES1 c.428G>A SNV. Consistently, in a recent in vitro
study, CES1 hydrolyzed ramipril about 10 times more efficiently than trandolapril or
enalapril (Thomsen et al. 2014).
6.4 Effects of CES1 genetic variants on its expression, and
clopidogrel pharmacokinetics and pharmacodynamics (Study IV)
Sequence variations in close proximity to or within the CES1 gene affect its expression.
Using massively parallel sequencing, two intronic CES1 c.52+579A>G (rs12443580; MAF
of 35%) and c.257+885T>C (rs8192935; MAF of 31%) SNVs were discovered to be
strongly and independently associated with CES1 whole blood expression in two
independent whole blood sample cohorts. The mechanisms underlying these associations
may be that the SNVs directly affect CES1 transcription or that they are in LD with other
variants affecting CES1 expression. No upstream variants in LD with the rs8192935 SNV
(r2>0.30) and none of the upstream variants in LD with the rs12443580 SNV (r2>0.30),
however, were located at previously identified transcription factor binding sites (Hosokawa
et al. 2008, Maruichi et al. 2010, Xu et al. 2016).
The lack of effect of rs12443580 and rs8192935 variants on CES1 liver expression,
despite strong effects on whole blood expression, suggests tissue-specific transcriptional
regulation of CES1. It should be kept in mind that our whole blood samples were from
healthy volunteers and the liver samples were from patients with variable degrees of hepatic
steatosis and inflammation. Neither these characteristics, nor age, sex, BMI, type 2
diabetes, or use of lipid-lowering medication, however, affected CES1 liver expression. It
was not possible to investigate whether CES1 liver expression levels correlated with CES1
whole blood expression, since the study did not include whole blood RNA samples from
the liver sample cohort patients.
The two SNVs affecting CES1 whole blood expression had no effect on the
pharmacokinetics or pharmacodynamics of clopidogrel, consistent with the lack of effect
on CES1 liver expression and the hypothesis that the CES1-mediated hydrolysis of
clopidogrel mainly takes place in the liver.  In contrast, the CES1 c.428G>A missense SNV
significantly impaired the hydrolysis of clopidogrel, increasing the exposure to clopidogrel
active metabolite and enhancing its platelet inhibitory effects. The CYP2C19 c.681G>A
loss-of-function allele was also significantly associated with reduced clopidogrel
antiplatelet effects, but it had no observable effect on exposure to the active metabolite.
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Notably, the effect of the CES1 c.428G>A SNV on clopidogrel antiplatelet effects is
opposite to, and stronger than that caused by the CYP2C19 c.681G>A variant allele.
6.5 Ethical considerations
All participants received both oral and written information and gave written informed
consent before entering the studies. The study protocols were approved by the Coordinating
Ethics Committee of the Helsinki and Uusimaa Hospital District (Studies I-IV) and by the
Ethics Committee of the Northern Savo Hospital District (liver sample cohort; Study IV).
The pharmacokinetic studies were also approved by the Finnish Medicines Agency Fimea
(Studies I-IV).
6.6 Clinical implications
The identification and characterization of the CES1 genetic variations affecting its
expression and activity may improve drug efficacy and reduce the risk of adverse effects.
The impaired bioactivation of oseltamivir in the CES1 c.428G>A variant allele carriers
could be important to the antiviral efficacy and toxicity of oseltamivir. It is possible that
the lower concentrations of oseltamivir carboxylate in c.428G>A variant allele carriers
translate into an increased risk of drug resistance. Moreover, oseltamivir treatment is
associated with neuropsychiatric reactions and even suicides in adolescents (Izumi et al.
2007). The parent oseltamivir has a relatively high lipophilicity and passive permeability
through cell membranes. It is possible that the increased plasma concentrations of
oseltamivir in CES1 c.428G>A allele carriers, and especially in homozygotes, could result
in an increased penetration of oseltamivir into the brain and increased risk of CNS toxicity.
The CES1 c.428G>A SNV markedly increased the clopidogrel active metabolite plasma
concentrations and antiplatelet effects by reducing the hydrolysis of parent clopidogrel to
the inactive carboxylic acid metabolite. Therefore, the CES1 c.428G>A allele might
increase clopidogrel efficacy and bleeding risk. Based on the more than 2-fold increased
exposure to the parent clopidogrel in CES1 c.428G>A carriers, it can be estimated that their
average clopidogrel dose requirement could be about 50% smaller than in noncarriers.
Of note, the pharmacokinetic studies on clopidogrel (Studies II and IV) were performed
in healthy young volunteers and not in the target population with atherothrombotic diseases.
Patients using clopidogrel are also likely to use other drugs and the effects of the CES1
c.428G>A SNV on clopidogrel could be modulated by CES1-mediated drug-drug
interactions. Several drugs used by patients on clopidogrel are known substrates or
inhibitors of CES1, including simvastatin, diltiazem, and carvedilol (Fukami et al. 2010,
Yanjiao et al. 2013, Thomsen et al. 2014). Use of ACE inhibitors was associated with an
increased risk of clinically significant bleeding in patients co-treated with ACE inhibitors
and clopidogrel, suggesting a possible CES1-mediated drug-drug interaction (Kristensen et
al. 2014), but this finding was not replicated in another study (Cressman et al. 2015). It is
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reasonable to assume that the CES1 c.428G>A SNV can also increase the antiplatelet
effects of clopidogrel in patients.
The CES1 c.428G/A SNV also decreases active enalaprilat plasma concentrations, but
has no observable effect on quinapril. Furthermore, it is possible that the hydrolysis of
enalapril is reduced to an even greater extent in CES1 c.428A/A homozygotes, potentially
leading to a reduced antihypertensive efficacy.
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7 CONCLUSIONS
The following conclusions can be made based on the studies in this thesis:
1. The CES1 c.428G>A SNV occurs at a minor allele frequency of 2.2% in the Finnish
population.
2. The CES1 c.428G>A SNV affects the pharmacokinetics of oseltamivir by impairing
the bioactivation of oseltamivir to its active oseltamivir carboxylate metabolite. The
CES1 c.428G>A SNV significantly affects the pharmacokinetics and
pharmacodynamics of clopidogrel by shifting its metabolism from the hydrolytic
pathway to the oxidative activating pathway. Therefore, the CES1 c.428G>A SNV
may increase the efficacy and risk of adverse effects of clopidogrel. The CES1
c.428G>A SNV significantly reduces the hydrolysis of enalapril to active
enalaprilat, but has no observable effect on quinapril hydrolysis. This suggests that
ACE inhibitors differ in their liability to the effects of the CES1 c.428G>A SNV.
3. Clopidogrel pharmacokinetics are highly sensitive to CES1 c.428G>A variant,
indicating that it can potentially be used as a CES1 probe substrate in humans.
4. The CES1 rs12443580 and rs8192935 variants have a major effect on CES1
expression in whole blood, but not in the liver, suggesting tissue-specific effects of
these SNVs. This could lead to substrate-dependent effects of these SNVs on drug
biotransformation.
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